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ABSTRACT 
 
The 2-aryl-6,8-dibromoquinazolin-4(3H)-ones were prepared in a single-pot operation by 
condensing 6,8-dibromoanthranilamide and aryl aldehydes in the presence of molecular 
iodine in ethanol. Treatment of the 2-aryl-6,8-dibromoquinazolin-4(3H)-ones with 
thionylchloride in the presence of dimethylformamide afforded the corresponding 2-aryl-4-
chloro-6,8-dibromoquinazolines. Palladium(0)-copper iodide catalysed Sonogashira cross-
coupling reaction of 2-aryl-4-chloro-6,8-dibromoquinazolines with terminal alkynes at room 
temperature afforded series of 2-aryl-6,8-dibromo-4-(alkynyl)quinazolines. Further 
transformation of the 2-aryl-6,8-dibromo-4-(phenylethynyl)quinazolines via Suzuki-Miyaura 
cross-coupling  with arylboronic acids occurred without selectivity to afford the 
corresponding 2,6,8-triaryl-4-(phenylethynyl)quinazolines. The compounds were 
characterized using a combination of NMR (
1
H and 
13
C) and IR spectroscopic techniques as 
well as mass spectrometry. The absorption and emission properties of 2,6,8-triaryl-4-
(phenylethynyl)quinazolines were determined in solution. 
 
Keywords: 2-aryl-6,8-dibromoquinazolin-4(3H)-ones; 2-aryl-4-chloro-6,8-
dibromoquinazolines; 2-aryl-6,8-dibromo-4-(phenylethynyl)quinazolines; 2,6,8-triaryl-4-
(phenylethynyl)quinazolines; Sonogashira cross-coupling reaction; Suzuki-Miyaura cross-
coupling reaction; absorption and emission properties 
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CHAPTER 1   INTRODUCTION 
 
Organic heterocyclic compounds comprise a vast field for the search of new materials 
possessing diverse applications, such as pharmaceutical products,
1
 agrochemical products
2
 
and organic light-emitting materials.
3,4
 Although several methods have been developed for 
the synthesis of polysubstituted quinazoline derivatives, to our knowledge, there are no 
derivatives bearing two aryl rings on the fused benzo ring. The main focus of the current 
investigation is on the design and synthesis of polyaryl substituted quinazolines, in which the 
electron-deficient quinazoline framework is linked to the 4-phenyl ring via a π-conjugated 
spacer and to the 2-, 6- and 8-aryl rings directly to afford donor-acceptor systems. It is 
envisaged that the prepared compounds would exhibit interesting photophysical properties. 
The challenge in synthesizing the desired tetraaryl substituted quinazolines is that the 
preformed quinazoline moiety must be suitably functionalized to allow directed metal- 
catalyzed cross-coupling reactions. In this investigation, attention is focused on methods that 
involve the use of 2-aryl-6,8-dibromo-4-chloroquinazolines as precursors for sequential metal 
catalyzed C-C bond formation.  
 
1.1  Structure and application of quinazoline derivatives 
 
Quinazoline is a compound made up of two fused aromatic rings, that is, the benzene and the 
pyrimidine ring. It was first prepared by Gabriel in 1903 and isolated from the Chinese plant 
aseru.
1
 The quinazoline scaffold is one of the most encountered moieties in medicinally 
important compounds with a wide range of biological properties including cardiovascular,
2
 
anti-cancer,
3
 anti-bacterial,
4
 anti-malarial
5
 and anti-inflammatory activities.
6,7 
Prazosin 1, for 
2 
 
example, was found to possess antihypertensive activity and it is a sympatholytic drug used 
for the treatment of high blood pressure.
8
 In addition,
 
Prazosin is a prototype of several 
quinazoline based antihypertensive drugs such as Terazosin, Doxazosin and Trimazosin.
4
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      1 
The study on 4-anilinoquinazoline derivatives as inhibitors of tyrosine kinase activity of 
epidermal growth factor receptor (EGFR) resulted in the approval of Gefitinib 2 for the 
treatment of lung cancer.
9 
Protein tyrosine kinases are enzymes involved in many cellular 
processes and are known to be activated in cancer cells to drive tumour growth and 
progression.
10 
Blocking tyrosine kinase activity therefore represents a rational approach to 
cancer therapy. Erlotinib or Tarceva 3, a 4-anilinoquinazoline derivative bearing an alkynyl 
moiety on the aniline ring, is also known as a tyrosine kinase inhibitor which acts on the 
epidermal growth factor receptor.
9
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A series of quinazolines bearing a thiophenoxy group at position 4 and a trichloromethyl 
group at position 2 were synthesized and found to exhibit antiplasmodial activity in vitro.
11   
 
4-(4-Chlorophenylthio)-2-(trichloromethyl)quinazoline 4, for example, appears to be a new 
promising candidate for the development of anti-malaria pharmacophores. 
N
N
CCl3
S
Cl
 
        4 
Biological activity of quinazolines is not only restricted to heteroatom-substituted derivatives. 
During the course of the exploration of non-anilino quinazoline scaffolds, trisubstituted 
quinazoline derivatives such as 4-(3-bromophenyl)-8-(trifluoromethyl)-2-phenylquinazoline
 
5 
were prepared as part of a series of liver X receptor modulators.
12
 4-Alkynylquinazolines 6 
were found to be potent EGFR tyrosine kinase inhibitors.
13
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     5        6 (R= Ph, CH2-O-Ph, C(Me)2CH2Ph) 
Heterocyclic compounds with intramolecular charge transfer properties, on the other hand, 
have attracted considerable attention for potential applications in organic electroluminescent 
diodes,
14
 organic solar cells,
15,16
 polarity probes
17
 and nonlinear optics.
18 
Polysubstituted 
quinolines in which an electron acceptor 2-aryl-4-methoxyquinoline framework is linked to  
4 
 
the  π-conjugated spacer through positions 6 and 8 to form donor-π-acceptor systems were 
reported as precursors for compounds with potential photonic or electronic properties.
19
 The                                                                                                                                                                                   
substitution of a phenyl fragment in stillbene with a nitrogen-containing heterocyclic unit has 
been established to have a significant effect on their photophysical properties, due to the 
involvement of the n→π* electronic state.20 The photophysical properties of 2-
styrylquinazolin-4(3H)-ones have been reported and these compounds can be regarded as 
candidates for organic electroluminescent diodes.
21
 5-Phenyl-2-(pyridin-2-yl)-5,6-
dihydro[1,2,4]triazolo-[1,5-c]-quinazoline 7, a heteroannulated  quinazoline derivative, was 
found to represent a new class of luminescent compounds in the solid state and in solution.
22
  
Compound 7 can therefore be recommended as a molecular probe and fluorescent label in 
microbiological assays. 
N
H
N
N
N
N
 
7 
Owing to their diverse applications, the development of methods for the synthesis of 
quinazoline derivatives has attracted considerable attention over the years. Diverse synthetic 
approaches towards the construction of quinazoline skeletons have been reported in the 
literature and the common procedure involves the oxidative aromatization of the 
corresponding quinazolinone precursors.  
 
 
5 
 
1.2 Synthesis of quinazolin-4-one derivatives 
 
The most general method for the synthesis of quinazolinones involves cyclocondensation of 
anthranilamide derivatives with aldehydes in the presence of various reagents such as p-
toluenesulfonic acid,
23
 sodium bisulfite (NaHSO3),
24
 or manganese dioxide (MnO2),
25
 etc. 
 
1.2.1  Methods for the synthesis of quinazolin-4(1H)-ones 
 
A number of methods for the synthesis of quinazolin-4(1H)-ones have been reported in 
literature including reductive cyclization and metal-mediated reactions. The condensation of 
anthranilamide 8 with salicyladehyde 9 in the presence of p-toluenesulfonic acid (p-TsOH) as 
a catalyst in ethanol at reflux afforded 2-hydroxyphenyl-2,3-dihydroquinazolin-4(1H)-one 10 
(Scheme 1).
23 
p-TsOH is an easily available and cheap reagent, which is used as a catalyst to 
promote the cyclocondensation of anthranilamide derivatives with carbonyl containing 
compounds. 
NH2
NH2
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+
OH
H O
N
H
NH
O
HO
(i)
 
                                      8     9            10 
Reagents and conditions: (i) p-TsOH, EtOH, reflux, 1 h. 
Scheme 1: Synthesis of 2-hydroxyphenyl-2,3-dihydroquinazolin-4(1H)-one using p-TsOH as 
a catalyst 
6 
 
Reductive cyclisation of anthranilamide 8 and aldehydes 11 using silica-supported ferric 
chloride (SiO2-FeCl3) as catalyst under solvent-free conditions afforded the 2,3-
dihydroquinazolin-4(1H)-one derivatives 12 (Scheme 2).
26 
Iron(III) chloride is a strong Lewis 
acid which promotes the cyclocondensation.  
NH2
NH2
O
+ Ar CHO
N
H
NH
O
Ar
(i)
 
                                     8     11           12                                       
Reagents and conditions: (i) SiO2-FeCl3, solvent-free, 80 °C. 
Scheme 2: SiO2-FeCl3 catalysed synthesis of 2,3-dihydroquinazolin-4(1H)-ones under 
solvent-free conditions 
 
During the course of studies on green chemistry, M. Wang et al. developed a new procedure 
for the synthesis of 2-substituted 2,3-dihydroquinazolin-4(1H)-ones 14, which involves the 
grinding of anthranilamide 8 with aldehydes or ketones 13 at room temperature in the 
presence of cerium(IV) ammonium nitrate (CAN) and water. The reaction mixture was later 
heated at 60 °C until completion of the transformation (Scheme 3).
27
 Cerium(IV) ammonium 
nitrate is a versatile single-electron oxidant  that promotes the cyclisation of anthranilamide 
derivatives with carbonyl containing compounds. The grinding step was found to be essential 
to increase the surface area and lead to increased yields. 
 
 
 
7 
 
NH2
NH2
O
+
N
H
NH
O
R
O
R'R
R'(i)
 
                                    8    13               14                                
Reagents and conditions: (i) CAN, Grinding. 
Scheme 3: CAN-mediated synthesis of 2,3-dihydroquinazolin-4(1H)-ones  
 
The reaction of o-nitrobenzamide 15 and cyclic ketone 16 in the presence of low valent 
titanium prepared from titanium tetrachloride and zinc powder in anhydrous THF afforded 
2,2-polymethylene-2,3-dihydroquinazolin-4(1H)-one 17 (Scheme 4).
28
 Zinc metal is used to 
effect the reduction of o-nitrobenzamide to o-aminobenzamide.
29
 Low-valent titanium 
tetrachloride, on the other hand, activates the carbonyl group to promote  cyclocondensation. 
NO2
NH2
O
+
N
H
NH
O
O
(i)
 
                                      15  16      17                  
Reagents and conditions: (i) TiCl4-Zn, THF. 
Scheme 4: Low-valent titanium-promoted synthesis of quinazolin-4(3H)-ones  
 
The dihydroquinazolin-4(1H)-one core can allow different degrees of unsaturation via 
dehydrogenation or aromatization to afford the corresponding quinazolin-4(3H)-ones or the 
fully aromatic quinazolines. 
 
 
8 
 
1.2.2  Methods for the synthesis of quinazolin-4(3H)-ones 
 
Tautomeric quinazolin-4(3H)-ones can be obtained from the corresponding 
dihydroquinazolin-4(1H)-ones through dehydrogenation using an oxidizing reagent to 
introduce an unsaturation between N-1 and C-2 of the scaffold. Alternatively, quinazolin-
4(3H)-ones are prepared directly in a single-pot procedure from anthranilamide derivatives 
and various carbonyl compounds by oxidative cyclocondensation or transition metal-
catalyzed reactions. 
 
1.2.2.1 Indirect methods involving dehydrogenation of quinazolin-4(1H)-ones  
  
 2-Hydroxyarylquinazolin-4(3H)-one derivatives 20, for example, were prepared by the 
oxidation of the dihydro derivatives 18 with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) in ethanol at reflux (Scheme 5).
23
 DDQ acts as an oxidizing reagent to introduce an 
unsaturation between N-1 and C-2. However quinazolin-4-ones were reported to exist in two 
different forms: the lactam form (major) and the iminol form (minor).
30 
N
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NH
O
HO
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R2
(i)
 
             18           19 (iminol)   20 (lactam) 
Reagents and conditions: (i) DDQ, EtOH, reflux. 
Scheme 5: Synthesis of 2-hydroxyarylquinazolin-4(3H)-ones with DDQ 
9 
 
Similarly, the oxidation of 2,3-dihydroquinazolin-4(1H)-ones 21 with iron(III) chloride 
hexahydrate (2 equiv) as an oxidizing agent, in refluxing water afforded the 2-substituted 
quinazolin-4(3H)-ones 22 in 77 to 92% yield (Scheme 6).
31
 
N
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(i)
R R
 
                                                 21                          22 (R=H, CH3, C6H5, 4-HOC6H4)                                
Reagents and conditions: (i) FeCl3.6H2O, H2O, reflux. 
Scheme 6: Oxidation of 2,3-dihydroquinazolin-4(1H)-one with FeCl3.6H2O 
 
Although effective, the synthesis of quinazolin-4(3H)-ones by means of dehydrogenation of 
the corresponding quinazolin-4(1H)-ones involve the use of non-environmentally friendly 
oxidative reagents in large excess. To minimise the risk of pollution, methods for one-pot 
synthesis of quinazolin-4(3H)-ones continue to appear in the literature.  
 
1.2.2.2  Direct methods for the synthesis of quinazolin-4(3H)-ones  
 
The single-pot reaction of 2-aminobenzoic acid 23 with formamide at 150 °C was found to 
proceed through an o-amidine intermediate 24 to afford the quinazolin-4(3H)-one 25 in 59% 
yield (Scheme 7).
32 
 
 
10 
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                                     23          24            25 
Reagents and conditions: (i) H2N-CHO, 150 °C, 6 h. 
Scheme 7: Single-pot reaction of 2-aminobenzoic acid with formamide 
 
A mixture of anthranilamide 8 and aldehyde derivatives in refluxing ethanol for 3 hours 
afforded compounds 26 in 82 to 91% yield. The latter were converted within 2 hours to the 
corresponding quinazolin-4(3H)-ones 27 in the presence of copper chloride (3 equiv) in 
refluxing ethanol (Scheme 8).
33
 This procedure has the advantage of using low temperature to 
achieve complete conversion of anthranilamide. The use of high temperature may produce 
complex decomposition mixtures.
34 
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                                  8              26          27  
Reagents and conditions: (i) RCHO, EtOH, 78 °C (ii) CuCl2, EtOH, 78 °C. 
Scheme 8: Oxidative cyclization of anthranilamide and aldehydes with CuCl2 
  
Mehdi Bakavoli and his group reported the oxidative cyclocondensation of anthranilamide 8 
with aromatic aldehydes 28 in the presence of molecular iodine (1.2 equiv) (Scheme 9).
35
 
Iodine is a Lewis acid that promotes the cyclocondensation and also effects the 
dehydrogenation.   
11 
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                                    8         28                   29 
Reagents and conditions: (i) I2, EtOH, rt. 
Scheme 9: Iodine-promoted oxidative cyclization of anthranilamide and aldehydes  
 
Non-classical methods such as transition metal-catalyzed cyclocondensation have also been 
described in the literature and those are discussed below. 
 
1.2.2.3  Synthesis of quinazolin-4(3H)-ones via transition metal-catalyzed cyclocondensation 
 
X. Wei et al., reported the synthesis of 2-arylsubtituted quinazolin-4(3H)-ones 32 by 
copper(I) bromide catalyzed reaction of halobenzamides 30 and arylmethanamines 31 in the 
presence of potassium carbonate as a base in DMSO under air as the oxidant at 110 °C 
(Scheme 10).
36 
X
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+ Ar NH2
Ar
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R R
 
                                 30 (X=I, Br, Cl)       31                           32 
Reagents and conditions: (i) CuBr, K2CO3, DMSO, 110 °C, 8 h. 
Scheme 10: CuBr catalysed reaction of halobenzamides with arylmethanamines  
12 
 
A one-pot oxidative cyclization of anthranilamides 33 with primary alcohols 34 to afford 
quinazolin-4(3H)-ones 35 was successfully achieved using bis[pentamethylcyclopentadienyl 
iridium chloride] as a catalyst in refluxing xylene (Scheme 11).
37
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R2 OH
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                                      33  34            35 
Reagents and conditions: (i) [CpIrCl2]2, K2CO3, xylene, 140 °C, 62 h. 
Scheme 11: Iridium-catalyzed one-pot synthesis of quinazolin-4(3H)-ones  
 
W. Xiao-Feng et al. reported the synthesis of quinazolin-4(3H)-ones 37 from 2-
aminobenzamide 8 and aryl bromides 36 in the presence of palladium(II) acetate as a source 
of Pd(0) catalyst, butyldiadamantylphosphine (BuPAd2) and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) in DMF at 120 °C under 10 bar of CO (Scheme 12).38  
NH2
NH2
O
+
R
Br
(i)
N
NH
O
Ar
 
                                             8         36               37 
Reagents and conditions: (i) Pd(OAc)2, BuPAd2, DBU, CO, DMF, 120 °C, 16 h. 
Scheme 12: Palladium-catalyzed one-pot synthesis of quinazolin-4(3H)-ones  
 
The quinazolin-4(3H)-one nucleus is a key intermediate for the preparation of quinazolines 
through oxidative aromatization. 
 
13 
 
1.3  Synthesis of quinazolines 
 
Diverse synthetic approaches towards the construction of quinazoline skeleton have been 
reported in the literature using different starting materials, such as quinazolin-4(3H)-ones, N-
substituted anthranilamides and isatoic anhydride derivatives. 
 
1.3.1  Oxidative-aromatization of quinazolin-4(3H)-one derivatives 
 
4-Halogenoquinazolines are important intermediates in the synthesis of substituted 
quinazolines due to the increased reactivity of the C-X bond towards various nucleophiles. 
The common method for the preparation of 4-chloroquinazoline derivatives involves 
oxidative aromatization of the corresponding quinazolin-4(3H)-ones using reagents such as 
thionyl chloride (SOCl2),
39
 phosphoryl chloride (POCl3)
40,41 
or a combination of phosphorus 
pentachloride (PCl5) and phosphoryl chloride (POCl3).
42,43
 The synthesis of  3-(6,8-dibromo-
4-chloroquinazolin-2-yl)-2-propenoic acid 39, for example, was achieved via the 
aromatization of the quinazolin-4(3H)-one precursor 38 using a mixture of POCl3 and PCl5 in 
a boiling water bath (Scheme 13).
42 
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Br
 
                                38              39              
Reagents and conditions: (i) POCl3, PCl5, 70 °C. 
Scheme 13: Oxidative aromatization of quinazolin-4(3H)-one 38 with PCl5 and POCl3 
14 
 
The reaction of 2-trichloromethylquinazolin-4(3H)-one 40 with either tetrabutylammonium 
bromide (TBABr) or tetrabutylammonium iodide (TBAI) in the presence of phosphorus 
pentoxide (P2O5) in toluene, on the other hand, afforded the corresponding brominated or 
iodinated quinazoline derivatives 41 or 42, respectively (Scheme 14).
44 
N
NH
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CCl3 N
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(i) (ii)
 
                            41    40           42 
Reagents and conditions: (i) TBABr, P2O5, toluene. (ii) TBAI, P2O5, toluene. 
Scheme 14: Oxidative aromatization of quinazolin-4(3H)-one 40 with TBABr or TBAI 
 
In addition to undergoing nucleophilic displacement of the 4-halogeno atom with various 
heteroatom-containing nucleophiles,
40,41,44 
 the 4-halogenoquinazolines easily undergo metal-
catalyzed cross-coupling to afford carbo-substituted quinazoline derivatives. 
46
 
 
1.3.2 Direct synthesis of quinazolines from substituted anthranilamide derivatives                                             
 
The microwave-assisted reaction of N-(2-acetylphenyl)alkylamide 43 and ammonium 
formate was found to proceed via the formation of an imine intermediate 44 to afford the 2,4-
dialkyl or -aryl quinazolines 45 in 50 to 65% yield (Scheme 15).
47
 During the course of this 
reaction, ammonium formate is decomposed at high temperature  to form ammonia which 
generates the imine that cyclises in the acid environment due to the presence of excess 
ammonium formate. 
15 
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                            43         44       45 
Reagents and conditions: (i) HCOONH4, MW 150 °C, 3 to 9 min (ii) HCOOH.  
Scheme 15: Microwave-assisted synthesis of 2,4-disubstitutedquinazolines 
 
The reaction of 2-aminobenzonitrile 46 with aniline in the presence of aluminium chloride 
afforded 2-amino-N-phenylbenzamidine 47, which upon heating with NaOH in formic acid 
yielded 4-phenylaminoquinazoline 48 (Scheme 16).
48 
CN
NH2 NH2
N
NH2
N
N
HN
C6H5
C6H5
(i) (ii)
 
                               46            47       48 
Reagents and conditions: (i) C6H5NH2, AlCl3, 180 °C (ii) HCOOH, NaOH, 90 °C, 2 h. 
Scheme 16: Synthesis of 4-phenylaminoquinazoline from 2-aminobenzonitrile and aniline 
 
A one-pot cyclisation involving heating of 2-amino-N-(3-chlorophenyl)benzamidine 49 with 
isatoic anhydride 50 in absolute ethanol afforded 2-(2-aminophenyl)-N-(3-
chlorophenyl)quinazolin-4-amine 51 in 70% yield (Scheme 17).
49
                                    
16 
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                       49              50             51 
 Reagents and conditions: (i) EtOH, 180 °C, 3 h. 
Scheme 17: Reaction of 2-amino-3-chlorophenylbenzimidamide with isatoic anhydride 
 
The 4-alkyl/arylaminoquinazolines are also commonly prepared through dechloroamination 
of the corresponding 4-chloroquinazolines. The condensation of 2-carboxyvinyl-4-chloro-
6,8-dibromoquinazoline 38 with ethanolamine in boiling ethanol, afforded the alkyl amino 
derivative 52 in 72% yield (Scheme 18).
42
 The nitrogen atom of the ethanolamine  is more 
nucleophilic than the more electronegative oxygen atom. 
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                               38              52   
Reagents and conditions: (i) H2N(CH2)2OH, EtOH, 80 °C. 
Scheme 18: Condensation of 2-carboxyvinyl-4-chloro-6,8-dibromoquinazoline with 
ethanolamine 
 
17 
 
The reaction of 4-chloro-2-(trichloromethyl)quinazoline 53 and 4-chlorothiophenol 54 in 
DMSO under nitrogen atmosphere at room temperature  afforded  4-(4-chlorophenylthio)-2-
(trichloromethyl)quinazoline 55 in 68% yield (Scheme 19).
11  
N
N
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CCl3
SH
Cl
N
N
Cl
CCl3
(i)
+
C6H4Cl
 
                                   53       54        55 
Reagents and conditions: (i) NaH, DMSO, N2, rt, 1 h 20 min. 
Scheme 19: Preparation of 4-(4-chlorophenylthio)-2-(trichloromethyl)quinazoline 
 
Halogenated quinazolines also constitute important substrates for structural elaboration via 
metal-catalyzed carbon-carbon bond formation to afford novel polysubstituted quinazolines 
as described below. 
 
1.3.3  Synthesis of carbo-substituted quinazoline derivatives via metal-catalyzed cross-
coupling reactions 
 
The development of metal-catalyzed cross-coupling reactions over the past decade has 
revolutionized the way carbon-carbon bonds are formed. Kumada, Negishi, Suzuki-Miyaura, 
Stille, and Sonogashira cross-coupling reactions represent powerful synthetic tools for the 
construction of highly substituted heterocycles.
50 
The mechanism for metal-catalyzed cross-
coupling usually occurs in three steps, namely, oxidative addition, transmetallation and reductive 
elimination. In the case of palladium cross coupling reactions, a catalytically active 14-electron 
18 
 
Pd(0) species is first generated from a pre-catalyst, either by ligand dissociation for Pd(0) 
precursors (Scheme 20) or by palladium reduction for Pd(II) precursors (Scheme 21). A wide 
range of palladium(0) catalysts or  precursors are used  for cross-coupling reaction. Pd(PPh3)4 is 
most commonly used, but PdCl2(PPh3)2 and Pd(OAc)2 plus PPh3  or   other  phosphine  ligands  
are  also efficient since they  are stable to  air and readily reduced to the active Pd(0) complexes 
with  phosphines.
51
 
Pd(0)L4 Pd(0)L3 Pd(0)L2
18-electron
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16-electron
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14-electron
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Scheme 20: Palladium ligand dissociation 
Pd(II)(OAc)2
2L
AcO Pd(II)
L
L
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+
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Scheme 21: Palladium reduction of Pd(OAc)2 
The palladium cross-coupling start with oxidative addition of the active palladium(0) catalyst 
Pd(0)L2 A to the aryl halide (Figure 1). During this step, the Csp
2
-X bond breaks and a 
palladium(II) complex trans-R1Pd(II)L2X B bearing both aryl and halide components as ligands. 
The rate of the oxidative addition is influenced by the reactivity of the aryl halide and the nature 
of the ligand present in the palladium(0) precursor.
51
 An order of reactivity of aryl halides is in 
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agreement with the C-X bond strengths. Likewise, alkylphosphine ligands are known to increase 
the electron density of palladium and, in turn, accelerate the oxidative addition step. The 
palladium(II) complex B formed is a 16-electron tetra-coordinated and square-planar species 
which can undergoes transmetallation via ligand exchange process with the aid of a base to 
formed an organopalladium(II) complex R1Pd(II)L2Nu C (Figure 1). The organic ligands of 
compound C are trans oriented and are converted to cis in a trans-cis isomerization to form 
isomer D. In the final step, known as reductive elimination, the organopalladium(II) complex cis-
R1Pd(II)L2Nu D releases the coupled product and regenerates the catalyst Pd(0). An increase of 
the electron density at the metal center facilitates the reductive elimination. Alkylphosphine 
ligands are known to coordinate with palladium and increase its electron density more than 
arylphosphines.
51
 The general catalytic cycle for such reaction can be represented as follows: 
NuH
R1 X
R1 Nu
R1 Pd(II)
Pd(0)
Nu
R1 Pd(II) X
	reductive elimination
	oxidative 
addition
transmetallation
(ligand exchange)
baseH
L
L2
L
L
L
Palladium precatalyst (Pd(0) or Pd(II))
+ base
+
+ X
-
A
B
Ctrans
L Pd(II) Nu
R1
L
DCis
trans
 
Figure 1: Generalised cycle for palladium-catalysed cross coupling 
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1.3.3.1  Kumada cross-coupling reaction 
 
The Kumada cross-coupling reaction involves the reaction of an organohalide with an 
organomagnesium compound (Grignard reagent) to yield the cross-coupled product using a 
palladium or nickel species as a catalyst. The reaction of 4-chloro-2-phenylquinazoline 56 
with phenylmagnesium chloride 57 using anhydrous manganese chloride (MnCl2) or 
manganese chloride tetrahydrate (MnCl2.4H2O) in tetrahydrofuran (THF), for example, 
afforded 2,4-diphenylquinazoline 58 in 71% yield (Scheme 22).
52
 The reaction is complete 
within 1.5 hour because of the α-nitrogen effect that activates the C-4 position of the 
quinazoline ring. 
N
N
Cl
Ph
+ PhMgCl (4 equiv)
N
N
Ph
Ph
(i)
 
                                   56     57           58 
Reagents and conditions: (i) MnCl2 or MnCl2.4H2O, THF, 0 °C 1.5 h. 
Scheme 22: Manganese-catalyzed cross-coupling of 4-chloro-2-phenylquinazoline with   
phenylmagnesium chloride 
 
The mild reaction conditions as well as the lower cost of manganese chloride, as compared to 
palladium or nickel salts, render this transformation an attractive alternative for the synthesis 
of carbo-substituted heterocycles. However, due to the high nucleophilicity of Grignard 
reagents, limited functional groups can be tolerated on both of the coupling partners and this 
makes the Kumada cross-coupling less applicable.  
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1.3.3.2  Negishi cross-coupling reaction 
 
The Negishi cross-coupling is the reaction between an organohalide with an organozinc 
compound in the presence of a palladium or nickel catalyst.
53
 The alkylation at C-2 position 
of 4-substituted 2-chloro-6,7-dimethoxyquinazoline 59 was achieved via Negishi cross-
coupling with methyl lithium and zinc(II) chloride using tetrakis(triphenylphosphine) 
palladium(0) [Pd(PPh3)4] as a catalyst in dioxane to afford the coupled product 60 (Scheme 
23).
54 
N
N
H3CO
H3CO
R
Cl N
N
H3CO
H3CO
R
CH3
(i)
 
                                                     59     60 
Reagents and conditions: (i) MeLi, ZnCl2, Pd(PPh3)4, dioxane. 
Scheme 23: Palladium-catalyzed cross-coupling of 4-substituted 2-chloro-6,7-
dimethoxyquinazoline 59 with MeLi and ZnCl2 
 
The main drawbacks of organozinc reagents are their incompatibility with a number of 
functional groups and their sensitivity to water and air. 
 
1.3.3.3  Suzuki-Miyaura cross-coupling reaction 
 
Palladium-catalyzed Suzuki-Miyaura cross-coupling reaction between organoboron 
compounds and organic halides or triflates is a general and efficient method for the formation 
of Csp
2–Csp2 bonds.55 This cross-coupling reaction has several advantages including 
22 
 
functional group compatibility, low toxicity of reagents and intermediates, easy availability 
of boron derivatives, high thermal stability and good tolerance toward oxygen and aqueous 
solvents.
56 
The reaction has a wide application in organic syntheses, material and medicinal 
chemistry and it is still an area of intense research. P. Verhaeghe et al. subjected 4-chloro-2-
trichloromethylquinazoline 61 to Suzuki cross-coupling with arylboronic acids (2.5 equiv) in 
the presence of Pd(OAc)2 in DMF  to afford the corresponding 4-aryl-2-
trichloromethylquinazolines 62 in 50 to 65% yield (Scheme 24).
57
 Compounds 62 were found 
to exhibit antiplasmodial activity. 
N
N
CCl3
Cl
(i)
N
N
CCl3
Ar
 
                                                61       62 (Ar =C6H5, 4-FC6H4, 4-ClC6H4) 
Reagents and Conditions: (i) ArB(OH)2 (2.5 equiv), Cs2CO3, Pd(OAc)2, DMF, reflux, 2 h. 
Scheme 24: Suzuki-Miyaura cross-coupling of 4-aryl-2-trichloromethylquinazolines 
 
The Suzuki-Miyaura cross-coupling of 4,7-dichloro-2-(2-methylprop-1-enyl)-6-nitro 
quinazoline 63 with arylboronic acids (1.5 equiv), Na2CO3 and Pd(PPh3)4 in DME-ethanol 
(9:1, v/v) under microwave irradiation afforded the monosubstituted C-4 products 64 
exclusively in 48 to 63% yield (Scheme 25).
56
 In the case of the 4-methoxy derivative, the 
monosubstituted C-4 product was obtained using 1.2 equivalents of the 4-
methoxyphenylboronic acid. The use of 1.5 equivalents of the electron rich 4-
methoxyphenylboronic acid, on the other hand, afforded the monosubstituted product 64 in 
45% yield and the disubstituted product in 15% yield. The latter was obtained as the only 
product when using 4 equivalents of the 4-methoxyphenylboronic acid. 
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O2N
Cl N
N
Cl
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CH3
O2N
Cl N
N
Ar
CH3
CH3
(i)
 
                                       63               64 
Reagents and Conditions: (i) ArB(OH)2 (4 equiv), Na2CO3,  Pd(PPh3)4 , DME/ethanol (9:1, 
v/v), MW (300 W), 80 °C, 3 h. 
Scheme 25: Suzuki-Miyaura cross-coupling of 4,7-diarylquinazolines 
 
The Suzuki cross-coupling reaction of N-(3-fluorophenyl)-6-iodoquinazolin-4-amine 65 with 
4-methoxyphenylboronic acid 66 using Pd(OAc)2 as a catalyst and Cs2CO3 as a base in 
aqueous dioxane  led to N-(3-fluorophenyl)-6-(4-methoxyphenyl)quinazolin-4-amine 67 in 
70% yield (Scheme 26).
58 
N
N
HN F
I
N
N
HN F
O
O
B(OH)2
+
(i)
 
                        65     66       67 
Reagents and Conditions: (i) Cs2CO3, Pd(OAc)2, dioxane-water (3:1, v/v), reflux 30 min. 
Scheme 26: The Suzuki cross-coupling reaction of N-(3-fluorophenyl)-6-iodoquinazolin-4-
amine 
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1.3.3.4  Stille cross-coupling reaction  
 
The Stille cross-coupling involves a cross-coupling between organostannanes and organic 
halides in the presence of Pd catalyst.
59
 Attempts to achieve monosubstitution via the Stille 
cross-coupling of 6-bromo-2,4-dichloroquinazoline 68 with trimethylalane (1.2 equiv) in the 
presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] as a catalyst resulted in 
mixture of both the C-4 69 (47% yield) and C-6 70 (16% yield) cross-coupled products 
(Scheme 27).
60
 
N
N
Br
Cl
Cl N
N
Br
CH3
Cl N
N
H3C
CH3
Cl
+
(i)
 
                                 68                69     70 
Reagents and Conditions: (i) Al(CH3)3, Pd(PPh3)4, THF, reflux. 
Scheme 27: Regioselective alkylation of 6-bromo-2,4-dichloroquinazoline 
 
 1.3.3.5  Sonogashira cross-coupling reaction 
 
The Sonogashira coupling reaction of aryl halides with terminal acetylenes provides an 
effective route for Csp-Csp
2
 bond formation to afford arylalkynes and conjugated enynes.
61
 
The reaction is widely applied as a key step in natural product synthesis and the preparation 
of molecular organic materials.
62
 The use of both palladium and copper catalyst results in the 
increased reactivity of the reagents and the ability of the reaction to be carried out at room 
temperature. The alkynylation of 4-chloroquinazoline 71 with various terminal alkynes 72 
(1.5 equiv) was achieved in the presence of palladium catalyst, with copper(I) iodide as a co-
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catalyst and triethylamine (Et3N) as a base in DMF to afford the 4-alkynylquinazolines 73 as 
new scaffolds for potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(Scheme 28).
62
 
N
N
Cl
R1O
R1O N
N
R1O
R1O
X
C6H5
+
C6H5
X
(i)
 
                                            71  72       73 (X= -(CH2)2-, 4- ClC6H4-, -CH2O-)       
Reagents and conditions: Et3N, Pd(PPh3)4, CuI, DMF, rt. 
Scheme 28: Sonogashira cross-coupling of 6,7-disubtituted-4-chloroquinazoline 
 
Attempted Sonogashira cross-coupling reaction between 4-chloro-2-trichloromethyl- 
quinazoline 61 and phenylacetylene 74 using triethylamine as a base, tetrakis(triphenyl- 
phosphine)palladium(0) [Pd(PPh3)4] as a source of a reactive Pd(0) species and copper(I) 
iodide (CuI) as a co-catalyst in THF  under nitrogen atmosphere did not afford the expected 
cross-coupled product.
44
 The presence of the trichloromethyl group at position 2 was found to 
complicate the outcome of this reaction. The use of cesium carbonate (Cs2CO3) as a base and 
palladium(II) acetate [Pd(OAc)2] as a catalyst in dimethylformamide (DMF), on the other 
hand, afforded the cross-coupled product 75 in low yield (15%) along with other undesirable 
products (Scheme 29).
44
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C6H5
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                                        61            74     75 
Reagents and conditions: (i) Cs2CO3, Pd(OAc)2, CuI, DMF, N2, rt, 3 h. 
Scheme 29: Sonogashira cross-coupling reaction of 4-chloro-2-trichloromethylquinazoline 
 
The selective mono-alkynylation of 6-bromo-2,4-dichloroquinazoline 68 with tert-butyl acetylene 
76 in the presence of bis(tryphenylphosphine)palladium(II) dichloride [PdCl2(PPh3)2] and 
copper(I) iodide  as catalyst complex and triethylamine  as a base in THF at room temperature 
afforded the C-4 substituted product 77 in 67% yield (Scheme 30).
63
 The selectivity of Pd-
catalyzed cross-coupling favours C-4 substitution due to α-nitrogen effect. On the other hand, 
heating the reaction mixture of 6-bromo-2,4-dichloroquinazoline with tert-butyl acetylene at 65 
°C afforded the trisalkynylated derivative 78 in 54% yield (Scheme 30).63 
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               78 
Reagents and conditions: (i) Et3N, PdCl2(PPh3)2, CuI, THF, 20 h, rt. (ii) PdCl2(PPh3)2, CuI, 
Et3N, THF, 20 h, 65 °C. 
Scheme 30:  Sonogashira cross-coupling reaction of 6-bromo-2,4-dichloroquinazoline  
 
1.4 Research objectives 
 
During our research on the development of polysubstituted heterocycles, we became 
interested in the synthesis of 2,4,6,8-tetrasubstituted quinazolines in which the electron-
deficient quinazoline framework is linked at C-4 to an aryl ring via π-conjugated spacer and 
directly at C-2, C-6 and C-8 to aryl rings to form donor-acceptor systems. Organic 
compounds with intramolecular charge transfer properties have potential applications
 
in 
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organic electroluminescent diodes,
14
 organic solar cells,
15,16
 polarity probes
64
 and nonlinear 
optics.
65
 A broad variety of donor-acceptor compounds with different configurations have 
been extensively developed because their absorption spectra and energy gaps can be tuned by 
controlling the intramolecular charge transfer from the electron donors to the electron 
acceptor.
19
 We envisioned that the 2-aryl-6,8-dibromo-4-chloroquinazolines represent 
suitable candidates for sequential Pd-catalyzed Sonogashira and Suzuki cross-coupling to 
afford the requisite polysubstituted quinazolines with potential photophysical properties. The 
main objectives of this investigation are to:  
(i) effect direct one-pot synthesis of the 2-aryl-6,8-dibromoquinazolin-4(3H)-ones using  
3,5-dibromoanthranilamide and substituted benzaldehydes as substrates, 
(ii) prepare the corresponding  2-aryl-6,8-dibromo-4-chloroquinazolines via oxidative-
aromatization of the 2-aryl-6,8-dibromoquinazolin-4(3H)-ones,   
(iii) subject the 2-aryl-6,8-dibromo-4-chloroquinazolines to sequential palladium catalyzed 
Sonogashira and Suzuki-Miyaura cross coupling reactions, and 
(iv) to study the absorption and emission properties of the resultant 2,4,6,8-tetrasubstituted 
quinazolines using UV-Vis and fluorescence spectroscopic techniques. 
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CHAPTER 2   RESULTS AND DISCUSSION 
 
Brief overviews of all the reaction steps undertaken in this investigation are summarized in 
scheme 31. The 2-aryl-6,8-dibromoquinazolin-4(3H)-ones 81a-d were prepared by condensing 
6,8-dibromoanthranilamide 79 and benzaldehyde derivatives 80a-d in the presence of molecular 
iodine in ethanol at 80 °C. Treatment of 2-aryl-6,8-dibromoquinazolin-4(3H)-ones 81a-d with 
thionyl chloride in the presence of DMF afforded the corresponding 2-aryl-4-chloro-6,8-
dibromoquinazolines 82a-d. The latter were, in turn, subjected to Sonogashira cross-coupling 
reaction with terminal alkynes in the presence of Pd(PPh3)4-CuI catalyst mixtures and Cs2CO3 as 
a base in THF at room temperature to afford novel 2-aryl-6,8-dibromo-4-(alkynyl)quinazolines 
83a-h. 
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Scheme 31: Generalized scheme illustrates reaction pathways followed to prepare the 
compounds described in this investigation 
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The 2-aryl-6,8-dibromo-4-(phenylethynyl) quinazolines 83a-d were subjected to Suzuki-
Miyaura cross-coupling with arylboronic acids  in the presence of PdCl2(PPh3)2-PCy3 catalyst 
complex  and K2CO3 in dioxane-water (3:1, v/v) to afford the corresponding 2,6,8-triaryl-4-
(phenylethynyl)quinazolines 84a-l. 
 
2.1 Synthesis of substrates  
 
2.1.1 Synthesis of 2-aryl-6,8-dibromoquinazolin-4(3H)-ones 
 
The first requirement of this investigation was to synthesize the 2-aryl-6,8-
dibromoquinazolin-4(3H)-ones 81a-d to be used as substrates for the 2-aryl-6,8-dibromo-4-
chloroquinazolines 82a-d. The quinazolin-4(3H)-one scaffold is generally accessible via 
dehydrogenation of the corresponding 2,3-dihydroquinazolin-4(1H)-one precursors using 
oxidants such as KMnO4,
66
 CuCl2
67 
and DDQ
68
 in stoichiometric quantities or in large excess. 
The 2-substituted quinazolin-4(3H)-ones have also been synthesized directly from 
anthranilamide and aldehydes using NaHSO3,
69
 DDQ,
23
 or I2
35 
as catalysts. In order to 
synthesize the required 2-aryl-6,8-dibromoquinazolin-4(3H)-ones, we needed 2-amino-3,5-
dibromobenzamide 79 as a precursor. 3,5-Dibromoanthranilamide analogue was previously 
prepared by reacting anthranilic acid with bromine in glacial acetic acid.
70
 However, because 
of the lack of selectivity of bromine, this reaction results in a mixture of mono- and 
dibromoanthranilic acids. The reaction of 2-aminobenzamide 8 with N-bromosuccinimide 
(NBS) in chloroform at room temperature afforded 2-amino-3,5-dibromobenzamide 79 in 
70% yield (Scheme 32). The amino group is a strong ortho/para director and this effect is 
relatively reinforced by the presence of the strong electron withdrawing amide group thus 
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activating both positions 3 and 5 for attack by the electrophilic bromide ion. The 
1
H NMR 
spectrum of compound 79 reveals the presence of a singlet at δ ca. 6.77 ppm integrating for 
two hydrogen atoms and corresponding to the protons of amino group (Figure 2). The 
singlets at  ca 7.72 ppm and  ca 7.77 ppm correspond to 4-H and 6-H, respectively. The 
amide protons resonate at  ca 7.47 ppm and 8.05 ppm. This non-equivalence between the 
two amide protons is due to the presence of an intramolecular hydrogen bond between the 
proton (Ha) at 8.05 ppm and the amine nitrogen in analogy with the literature precedent on 
the 2-aryliminocoumarin-3-carboxamides.
71
  
NH2
NH2
O
NH2
NH2
O
Br
Br
(i)
 
                                                                8          79 
Reagents and conditions: (i) NBS (2 equiv), CHCl3, rt, 3 h. 
Scheme 32: Bromination of 2-aminobenzamide with NBS 
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Figure 2: 
1
H NMR spectrum of 79 in DMSO-d6 at 300 MHz 
 
With 3,5-dibromoanthranilamide 79 in hand, we decided to investigate the possibility of 
synthesizing 2-aryl-6,8-dibroquinazolin-4(3H)-ones via one-pot cyclocondensation and 
dehydrogenation with benzaldehyde derivatives. Compounds 81a-d were prepared in a 
single-pot operation by the oxidative cyclocondensation of 2-amino-3,5-dibromobenzamide 
79 with benzaldehyde derivatives 80a-d in the presence of molecular iodine (2 equiv) in 
absolute ethanol at 80 °C (Scheme 33). Molecular iodine in this case serves as a catalyst to 
 
4-H 
6-H 
Ar-NH2 
Ha 
Hb 
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effect the cyclocondensation and as an oxidant to introduce dehydrogenation. The prepared 
compounds 81a-d were characterized using 
1
H NMR, IR, and mass spectroscopic techniques. 
Because of a poor solubility of 81a-d in DMSO-d6 we were not able to obtain their 
13
C NMR 
spectra. The 
1
H NMR spectra of products 81a-d reveal the presence of a singlet at δ ca. 12.94 
ppm corresponding to the N-H proton, and resonances in the region δ 7.11−8.39 ppm for the 
aromatic protons (Figure 3). Their amide nature is also confirmed by the presence of IR 
bands in the region ν
max 
1660−1680 cm-1 and ν
max 
1550−1595 cm-1 corresponding to C=O and 
C-N, respectively. The accurate calculated m/z values in each case are consistent with the 
observed molecular weight of the assigned structure. 
Br
Br
NH2
NH2
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+
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O H
(i)
N
NH
Br
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O
C6H4R
 
                             79     80         81a-d                                                                                                                                                                                                                      
81 R ν
max 
C=O (cm
-1
) ν
max
 C−N
 
(cm
-1
) % Yield mp. (ºC) 
a 4-H 1666 1592 80 332−335 
b 4-F 1676 1583 89 > 345 
c 4-Cl 1672 1558 94 > 345 
d 4-OCH3 1663 1556 89 302−304 
 
Reagents and conditions: (i) I2 (2 equiv), EtOH, 80 °C, 7 h. 
Scheme 33: Iodine-promoted oxidative cyclocondensation of 2-amino-3,5-dibromobenzamide 
with aldehydes  
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Figure 3: 
1
H NMR spectrum of 81b in DMSO-d6 at 300 MHz 
  
 2-Phenyl-6,8-dibromoquinazolin-4(3H)-one 81a was previously found to exhibit 
antibacterial and antiinflammatory properties.
72 
Moreover, the 2-substituted 6,8-
dibromoquinazolin-4(3H)-ones were reported as starting materials for the synthesis of a 
series of 2,4-disubstituted quinazolines as antibacterial and antifungal agents.
73 
Compounds 
81a-d represents suitable scaffolds for further dehydrogenation to afford the fully aromatic 
quinazoline derivatives. 
 
N-H 
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2.1.2 Synthesis of 2-aryl-4-chloro-6,8-dibromoquinazolines 
 
Several methods have been described for the synthesis of 4-chloroquinazolines via oxidative 
aromatization of the quinazolin-4(3H)-ones. 4-Chloro-5,7-difluoroquinazoline, for instance, 
was prepared following the condensation of 5,7-difluoroquinazolin-4(3H)-one in an excess of 
phosphoryl chloride (POCl3) in the presence of tertiary amine as a catalyst.
74 
 Attempted 
oxidative aromatization of compounds 81a-d with POCl3, POCl3−amine or POCl3−DMF 
mixtures under reflux led to incomplete conversion (tlc monitoring) to the requisite 4-
chloroquinazolines. The 4-chloroquinazolines 82a-d were prepared with thionyl chloride in 
the presence of trace amounts of DMF under reflux for 2 h (Scheme 34).
39 
The success of this 
transformation was confirmed by the absence of an N-H signal in the 
1
H NMR spectra of 
compounds 82a-d and the presence of additional aromatic proton signals in the region δ 
7.08−8.28 ppm (Figure 4). Moreover, the IR spectra of products 82a-d are characterized by 
the absence of the C=O stretch found in the spectra of the corresponding substrates. 
N
NH
O
Br
Br
C6H4R N
N
Cl
Br
Br
C6H4R
(i)
 
          81a-d                82a-d  
82 R % Yield mp. (°C) 
a 4-H 96 186-187 
b 4-F 81 206-208 
c 4-Cl 77 239-240 
d 4-OCH3 77 200-202 
 
Reagents and conditions: (i) SOCl2, DMF, 120 °C, 2 h. 
Scheme 34: Oxidative aromatization of 2-aryl-6,8-dibromoquinazolin-4(3H)-ones 
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Figure 4: 
1
H NMR spectrum of 82b in CDCl3 at 300 MHz 
 
It is well known in the literature that the C-4 position of the quinazoline moiety is highly 
electrophilic due to the -nitrogen effect.
56
 The reaction of 4-chloroquinazoline derivatives with 
hydrazine hydrate and subsequent condensation with different aromatic aldehydes furnished a 
series of fused 5-substituted-[1,2,4]triazoloquinazoline derivatives.
42
 Likewise, interaction of 6,8-
dibromo-4-chloro-2-methylquinazoline with acetyl acetone in boiling ethanol in the presence of 
sodium ethoxide as a catalyst afforded 6,8-dibromo-2-methyl-4-(diacetylmethyl)quinazoline.
73
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Moreover, compounds 82 represent suitable candidates for further transformation via metal 
catalyzed cross-coupling due to the presence of halogens at positions 4, 6 and 8. In this 
investigation, we focused our attention on the reactivity of compounds 82a-d in Sonogashira 
cross-coupling with terminal alkynes as models for Csp
2–Csp bond formation. 
 
2.2 Sonogashira cross-coupling of 2-aryl-4-chloro-6,8-dibromoquinazolines 
 
The choice of Sonogashira cross-coupling is based on the fact that this reaction occurs under 
mild conditions and can tolerate various functional groups. At first we reacted 4-chloro-6,8-
dibromo-2-phenylquinazoline 82a with phenylacetylene (1.2 equiv) using 
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] as a Pd(0) source, copper(I) iodide 
(CuI) as co-catalyst and Cs2CO3 as a base in DMF under nitrogen atmosphere at room 
temperature for 3 hours in analogy with previous literature procedure.
44
 We recovered the 
starting material 82a. We then reacted 82a with phenylacetylene (1.2 equiv) in the presence 
of Pd(PPh3)4, CuI and Cs2CO3 in THF under nitrogen atmosphere at room temperature for 24 
hours. Compound 83a was isolated in 59% yield and the reaction conditions were extended to 
other derivatives using phenylacetylene, 2-ethynylpyridine, and 3-butyn-2-ol as coupling 
partners to afford product 83b-h (Scheme 35). The 
1
H NMR spectra of compounds 83a-h 
reveal two singlets at δ ca. 8.28 and 8.47 ppm corresponding to 5-H and 7-H, respectively 
(Figure 5). The 
1
H NMR spectrum of 83h is also characterised by the presence of a doublet at 
δ ca. 1.70 ppm, a  singlet at δ ca. 2.35 ppm, and a quartet at δ ca. 4.94 ppm  corresponding to 
CH3, OH and CH of the 1-hydroxyethyl group, respectively. The 
13
C NMR spectra of 80a-h 
show, as expected, an increased number of resonances and the alkyne carbons resonating at δ 
ca. 84.9 ppm (≡C−R’), and 99.0 ppm (C(4)−C≡)  respectively (Figure 6). Likewise, their IR 
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spectra reveal the presence of an intense absorption band at ν
max
 2210 cm
-1
 which 
corresponds to the C–C triple bond (Figure 7). The accurately calculated m/z values in all 
cases confirm the replacement of the 4-Cl due to the absence of peaks attributed to the 
chlorine isotopes (m/z 35 and 37). On the other hand, the appearance of Br isotopes (m/z 79 
and 81) peaks confirmed the presence of two bromine atoms. 
N
N
Cl
Br
Br
C6H4R N
N
Br
Br
C6H4R
R'
(i)
 
                                         82a-d         83a-h 
83 R R΄ ν
max 
C≡C (cm-1) % Yield mp. (°C) 
a 4-H -C6H5 2215 59 186-187 
b 4-F -C6H5 2210 72 206-208 
c 4-Cl -C6H5 2209 70 239-240 
d 4-OCH3 -C6H5 2210 71 200-202 
e 4-H 2-pyridyl- 2228 65 207-209 
f 4-F 2-pyridyl- 2219 67 216-218 
g 4-OCH3 2-pyridyl- 2221 55 204-206 
h 4-H -CH(OH)CH3 2221 56 162-165 
 
Reagents and conditions: (i) R′C≡CH, Pd(PPh3)4, CuI, Cs2CO3, THF, rt, 24 h.  
Scheme 35: Sonogashira cross-coupling of 2-aryl-4-chloro-6,8-dibromoquinazolines with 
terminal akynes 
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Figure 5: 
1
H NMR spectrum of 83a in CDCl3 at 300 MHz 
 
7-H 
5-H 
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Figure 6: 
13
C NMR spectrum of 83a in CDCl3 at 75 MHz 
 
 
≡C−C6H5 C(4)−C≡ 
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Figure 7: IR spectrum of 83a 
 
Several examples of 2-substituted quinazolines bearing an alkynyl substituent at the C-4 
position have been reported to exhibit excellent epidermal growth factor receptor (EGFR) 
activity.
12
 The two bromine atoms on the fused benzo ring in compounds 83 makes them 
 
C≡C 
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suitable candidates for  subsequent elaboration via metal-catalyzed cross-coupling. We 
decided to investigate the reactivity of compounds 83 in palladium catalyzed Suzuki-Miyaura 
cross-coupling with arylboronic acids. 
 
2.3 Suzuki cross-coupling of 2-aryl-6,8-dibromo-4-(phenylethynyl)quinazolines 
  
The displacement of halogen atoms on dihalogenated heterocyclic compounds bearing 
different halogens via cross-coupling reactions is known to follow the trend: I > Br > Cl.
75 
The C-X bond dissociation energies decrease down the halogen group with the 
electronegativity. In the case of dihalogenated heterocycles bearing the same halogen atoms, 
the challenge is to study the reactivity of both halogens in a cross-coupling reaction. Suzuki 
cross-coupling of 6,8-dibromo-4-methoxy-2-phenylquinoline, for example, with 
arylvinylboronic acid (1 equiv) using Pd(PPh3)4 as Pd(0) source, led to the recovery of the 
starting material.
19
 The reaction failure was attributed to the inhibiting role of the extra PPh3 
generated from the ligand exchange between Pd(PPh3)4 and the solvent. However, the use of 
dichlorobis(triphenylphosphine)palladium(II) [PdCl2(PPh3)2] afforded the doubly coupled 
product and the starting material. The double coupled product, on the other hand, was 
obtained as a sole product with an excess of arylvinylboronic acid (2.5 equiv) in the presence 
of PdCl2(PPh3)2-tricyclohexylphosphine catalyst complex.
19
 Prompted by the above result, 
we decided to investigate the reactivity of the two bromine atoms of the 2-aryl-6,8-dibromo-
4-(phenylethynyl)quinazolines 83 via Suzuki cross-coupling with arylboronic acids. At first 
we reacted compounds 83a with phenylboronic acid (1.5 equiv) using PdCl2(PPh3)2-PCy3 as 
catalyst complex and K2CO3 as a base in dioxane under reflux. After 4 hours we isolated by 
column chromatography on silica gel, the 2,6,8-triphenyl-4-(phenylethynyl)quinazoline 84a 
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in 30% along with the starting material. This observation was found to compare with the 
previous literature data for the analogous 2-aryl-6,8-dibromo-4-methoxyquinolines.
19
 We 
then opted for the use of an excess arylboronic acid (2.5 equiv) on compounds 83a-d and we 
isolated the corresponding 2,6,8-triaryl-4-(phenylethynyl)quinazolines 84a-l in 57−78% yield 
(Scheme 36). The prepared compounds 84a-l were characterized using a combination of 
NMR (
1
H and 
13
C), IR and mass spectroscopic techniques. The 
1
H NMR spectra of products 
84a-l show an increase number of proton signals in the aromatic region δ ca. 6.86−8.03 ppm 
(Figure 8). The 
13
C NMR spectra also show an increase in the number of peaks in the 
aromatic region corresponding, in each case, to double aryl substitution on the fused benzo 
ring (Figure 9). Moreover, the absence of Br isotope peaks further confirms double aryl 
substitution. 
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N
N
R''C6H4
C6H4R''
C6H4R
C6H5
N
N
Br
Br
C6H4R
C6H5
(i)
 
                83a-d        84a-l 
                             
 
 
 
 
 
 
 
    
 
 
Reagents and conditions: (i) Ar΄΄B(OH)2, PdCl2(PPh3)2, PCy3, K2CO3, dioxane-H2O (3:1, 
v/v), 2 h. 
Scheme 36: Suzuki cross-coupling reaction of 2-aryl-6,8-dibromo-4-(phenylethynyl) 
quinazolines with arylboronic acids 
 
84 R΄΄ R % Yield mp. (°C) 
a 4-H 4-H 71 184-186 
b 4-H 4-F 57 250-252 
c 4-H 4-Cl 78 246-248 
d 4-H 4-OCH3 68 220-223 
e 4-F 4-H 66 228-230 
f 4-F 4-F 76 255-257 
g 4-F 4-Cl 75 243-245 
h 4-F 4-OCH3 65 211-213 
i 4-OCH3 4-H 69 209-212 
j 4-OCH3 4-F 62 236-239 
k 4-OCH3 4-Cl 76 233-235 
l 4-OCH3 4-OCH3 60 237-239 
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Youssef Kabri et al in a recent publication also describe the synthesis of 2,4,6,8-
tetrasubstitutedquinazolines via microwave-assisted consecutive bis-SNAr/bis-Suzuki-
Miyaura cross-coupling reactions of the 6,8-dibromo-2,4-dichloroquinazoline.
76
 
 
Figure 8: 
1
H NMR spectrum of 84a in CDCl3 at 300 MHz  
 
7-H 
46 
 
 
 
 
Figure 9: 
13
C NMR spectrum of 84a in CDCl3 at 75 MHz 
 
2,6,8-Triaryl-4-(phenylethynyl)quinazolines 84a-l comprise an electron-deficient quinazoline 
framework as an electron-acceptor linked directly to aryl rings or through the alkyne bridge 
to form donor-acceptor systems. We decided to determine the absorption and emission 
properties of compounds 84a-l in solvents of different polarity. 
 
C(4)−C≡ 
≡C−C6H5 
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2.4 Photophysical property studies of 2,6,8- triaryl-4-(phenylethynyl)quinazolines 
 
The absorption properties of compounds 84a-l were measured in chloroform (Figure 10-12) 
and methanol-chloroform (1:1, v/v) (Figure 13-15), whereas their emission properties were 
determined in chloroform (Figure 16-18) and DMF (Figure 19-21). Quantum yield and 
Stokes shift calculations to establish the effect of substituents on the absorption and emission 
properties of these polysubstituted quinazolines were also reported (Table 1). 
 
2.4.1 Absorption properties of 2,6,8-triaryl-4-(phenylethynyl)quinazolines 
 
Compounds 84a-l are characterized by intense absorption bands in the region λ 270−300 nm 
in CHCl3 which are due to π→π* transition, attributed to the conjugated quinazoline ring. In 
the case of phenyl derivatives 84a-d, the sharp peak observed for 84a and 84b is probably 
due to the presence of the less electron donating 2-phenyl or 2-(4-fluorophenyl) group as 
compared to 84c and 84d bearing a strong electron withdrawing 2-(4-chlorophenyl) and 
electron donating 2-(4-methoxyphenyl) groups respectively. However, the intensity of their 
absorption peaks decrease with the strong resonance effect of the aryl substituent at position 
2: 84a > 84b > 84c and 84d (Figure 10). A combination of the less electron donating 2-(4-
chlorophenyl) or 2-phenyl group and the relatively electron donating 4-fluorophenyl group at 
positions 6 and 8  enhance the absorptivities for 84g and 84e, respectively (Figure 11). A 
strong  electron donating 4-methoxyphenyl group at positions 6 and 8  seems to increase the 
electron density of the quinazoline ring for 84j and 84k (Figure 12) whereas the same group 
at position 2 decreases the electron density for 84d, 84h and 84l. On the other hand, the 
strong electron donating 4-methoxyphenyl group is also responsible for a blue shift observed 
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in solutions of compounds 84. Therefore, the strong electron donating group has a 
considerable effect on the conjugation of the π electron of the quinazoline scaffold. 
 
Figure 10: UV-Vis spectra of 84a-d in CHCl3 (2.2×10
-5
 mol/l) 
 
 
Figure 11: UV-Vis spectra of 84e-h in CHCl3 (2.2×10
-5
 mol/l) 
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Figure 12: UV-Vis spectra of 84i-l in CHCl3 (2.2×10
-5
 mol/l) 
 
Solvent effects on absorption spectra of compounds 84 have also been studied. In this 
investigation, we opted for a mixture methanol-chloroform (1:1, v/v) because of the poor 
solubility of these compounds in methanol. Solutions of compounds 84 are characterised by 
single absorption bands in the region λ 296−318 nm. The absorption spectra of compounds 
84 in methanol-chloroform solution are red shifted with lower intensities as compared to 
solutions of these compounds in chloroform. This observation indicates the relatively strong 
interaction between N-1 of the quinazoline receptor and the polar protic methanol sovent in a 
form of hydrogen-bonding. In addition, the spectral shifts of compounds 84d, 84h and 84l 
bearing a methoxy group are also attributed to hydrogen-bonding between oxygen of the 
donor 4-phenylmethoxy group with methanol (Figure 13, 14 and 15). The longest wavelength 
is observed for compound 84l bearing the strong electron donating 4-methoxyphenyl group at 
positions 2, 6 and 8 (Figure 15). In the case of phenyl derivatives 84a-d or 4-methoxyphenyl 
derivatives 84i-l, the broad band observed in 84c and 84k is due to the strong electron 
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withdrawing 4-chlorophenyl group at position 2 (Figure 13 and 15). Consequently, the 
solvent effect on absorption spectra of compounds 84 strongly depend on the nature of the 
substituent on the aryl groups. 
 
Figure 13: UV-Vis spectra of 84a-d in MeOH-CHCl3 (2.2×10
-5
 mol/l) 
 
 
Figure 14: UV-Vis spectra of 84e-h in MeOH-CHCl3 (2.2×10
-5
 mol/l) 
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Figure 15: UV-Vis spectra of 84i-l in MeOH-CHCl3 (2.2×10
-5
 mol/l) 
 
2.4.2 Emission properties of 2,6,8-triaryl-4-(phenylethynyl)quinazolines 
 
In order to investigate the emission properties of compounds 84a-l, the photoluminescence 
spectra of these compounds were obtained at room temperature in the non-polar chloroform 
(Figure 16-18) and in  the strongly polar DMF (Figure 19-21) at the excitation wavelengths   
λex = 380 nm and 400 nm, respectively. The spectra of compounds 84a-l show similar pattern 
and are characterized by single emission band in the region λ 450−480 nm in CHCl3 and 
450−500 nm in DMF. This observation is due to π→π* transition attributed to the conjugated 
quinazoline ring system. In CHCl3 compounds 84a, 84e and 84i bearing the relatively less 
electron donating 2-phenyl group exhibit relatively reduced emission intensities reflecting the 
following trend: 84i > 84e > 84a. This trend reflects the conjugative effect of the aryl group at 
positions 6 and 8. Moreover, Stokes shift and fluorescence quantum yield display the same 
trend (Table 1). The strong electron donating 2-(4-methoxyphenyl) group seems to enhance the 
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emission intensities of 84d, 84h and 84l as compared to the  moderately donating 2-(4-
fluorophenyl) (Figure 16, 17, 18). Nevertheless, in the case of 4-fluorophenyl derivatives, a 
strong electron donating group at position 2 causes a bathochromic shift for solutions of 
compounds 84. 
 
 
Figure 16: Emission spectra of 84a-d in CHCl3 (2.2×10
-5
 mol/l) 
 
 
Figure 17: Emission spectra of 84e-h in CHCl3 (2.2×10
-5
 mol/l) 
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Figure 18: Emission spectra of 84i-l in CHCl3 (2.2×10
-5
 mol/l) 
 
In the case of phenyl derivatives, the strong electron withdrawing 4-chlorophenyl group at 
position 2 causes a red shift in solutions of compounds 84. In DMF, a combination of the 
strong electron donating 2-(4-methoxyphenyl) group and the relatively less electron donating 
phenyl group at positions 6 and 8 of the benzo ring reduce the emission intensity of 84d as 
compared to 84h and 84l bearing the moderately and strongly electron donating 4-
fluorophenyl and 4-methoxyphenyl groups at positions 6 and 8, respectively. This 
observation can be attributed to the π-electron delocalization into the quinazoline ring caused 
by the electrons donating aryl substituents at positions 6 and 8. In the case of 4-methoxy 
derivatives 84i-l, the intensities of emission maxima seem to be influenced by the conjugative 
effect of the substituent 2-aryl group reflecting the following trend  84l > 84i > 84j > 84k 
(Figure 21). The emission spectra of compounds 84a-l in a strongly polar DMF exhibit lower 
intensities and are red shifted as compared to solution of the same compounds in CHCl3. 
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Figure 19: Emission spectra of 84a-d in DMF (2.2×10
-5
 mol/l) 
 
 
Figure 20: Emission spectra of 84e-h in DMF (2.2×10
-5
 mol/l) 
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Figure 21: Emission spectra of 84i-l in DMF (2.2×10
-5
 mol/l) 
 
The attachment of the electron donating 4-methoxyphenyl/4-trifluoromethylphenyl group at 
positions 1, 3, 5 and 9 of the electron deficient pyrene framework, for example, was found to 
lower the energy gap between the highest occupied and lowest unoccupied molecular 
orbitals (HOMO-LUMO) as compared to the phenyl group.
77
 The calculated energy gaps 
were 3.40 eV and 3.43 eV for the 4-methoxyphenyl/4-trifluoromethylphenyl and phenyl 
derivatives, respectively.
77
 The energy needed for the transition state electrons in the case of 
4-methoxyphenyl/4-trifluoromethylphenyl derivative is reduced and the emission spectra 
shift to longer wavelength. Based on this literature precedent, we attribute the red shift 
observed for compounds 84e-l bearing the strongly or moderately electron donating 4-
methoxyphenyl or 4-fluorophenyl group at positions 6 and 8 of the electron deficient 
quinazoline core to be due to the decrease in the HOMO-LUMO energy gap. To further 
understand the electronic properties of compounds 84a-l, density functional theory (DFT) 
calculations at B3LYP/6-31G* level
78
 were carried out
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0
200
400
600
800
380 430 480 530 580
E
m
is
si
o
n
 I
n
te
n
si
ty
 (
a
.u
. 
) 
Wavelength (nm) 
84i (R=H)
84j (R=F)
84k (R=Cl)
84l (R=OMe)
N
N
MeOC6H4
C6H4OMe
C6H4R
C6H5
56 
 
optimization.
79
 ZINDO/S calculations were performed in chloroform for the optimized 
configuration. The lowest-energy absorption transition at 373 nm in 84a, chosen as a 
representative model was best characterized by a transition from the HOMO to the LUMO. 
The optimized structures and orbital distributions of the HOMO and LUMO of 84a, 84f and 
84l are shown in figure 22. The HOMO levels mainly involved contributions of the π-
orbitals from the entire quinazoline while the LUMO move toward the quinazoline-based 
moiety as an electron acceptor representing the π*-orbitals.  
            
84a-HOMO    84f-HOMO   84l-HOMO 
 
            
    84a-LUMO    84f-LUMO   84l-LUMO 
Figure 22: Computed molecular orbital of 84a, 84f and 84l 
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84 λmax 
(nm) 
CHCl3 
λmax (nm) 
CH3OH-CHCl3  
(1:1, v/v) 
Molar Extinction 
Coefficient (ε)   
 dm
3
Mol
-1
cm
-1
 
λem (nm) 
CHCl3 
Stokes shift  Quantum yields  
(a)Φ  
λem (nm) 
DMF 
a 298 296.2 11.216×10
3
 454.5 156.5 0.071 456.5 
b 295.6 297.7 11.163×10
3
 455 159.4 0.078 459 
c 285.7 307.6 8.798×10
3
 462.5 176.8 0.102 467 
d 280.3 299.8 8.601×10
3
 455 174.7 0.105 458 
e 285.7 297.4 11.216×10
3
 454.5 168.8 0.071 457.5 
f 284.5 297.7 11.181×10
3
 456 171.5 0.081 457 
g 278.5 300.1 11.754×10
3
 455 176.5 0.076 458.5 
h 286.6 309.1 10.271×10
3
 463 176.4 0.088 466.5 
i 292.9 299.5 9.725×10
3
 478.5 185.6 0.088 503 
j 276.4 300.4 12.063×10
3
 479 202.6 0.072 504.5 
k 276.7 303.7 12.268×10
3
 480 203.3 0.070 505.5 
l 273.4 318.4 10.422×10
3
 479.5 206.1 0.081 496 
 
(a) Obtained by calculation, based on quinine sulfate in H2SO4 0.5 M as the standard  
 
Table 1: The absorption and emission data for compounds 84a-l 
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CHAPTER 3   CONCLUSION 
 
A single-pot iodine-mediated cyclocondensation of 2-amino-3,5-dibromobenzamide and 
subsequent dehydrogenation of the intermediate 2-aryl-6,8-dibromoquinazolin-4(1H)-one in 
ethanol to afford 2-aryl-6,8-dibromoquinazolin-4(3H)-one derivatives has been achieved. 
Molecular iodine serves as a Lewis acid to effect the cyclocondensation and at the same time acts 
as an oxidant to promote the dehydrogenation step. The oxidative aromatization of 2-aryl-6,8-
dibromoquinazolin-4(3H)-ones was achieved using thionyl chloride in the presence of DMF to 
afford novel 2-aryl-4-chloro-6,8-dibromoquinazolines. However, oxidative aromatization of 2-
aryl-6,8-dibromoquinazolin-4(3H)-ones with POCl3, POCl3-tertiary amine or POCl3-DMF 
mixture resulted in incomplete conversion. Selective alkynylation of the 2-aryl-4-chloro-6,8-
dibromoquinazolines was achieved via Sonogashira cross-coupling with alkyne derivatives to 
afford novel 2-aryl-6,8-dibromo-4-(alkynyl)quinazolines. The C-4 position of 2-aryl-4-chloro-6,8-
dibromoquinazolines is highly activated  due to α-nitrogen effect. The Suzuki-Miyaura cross-
coupling of 2-aryl-6,8-dibromo-4-(phenylethynyl)quinazolines with arylboronic acids occurs 
without selectivity to afford the corresponding novel 2,6,8-triaryl-4-(phenylethynyl)quinazoline 
derivatives. The lack of selectivity is presumably the consequence of comparable C(6)-Br and 
C(8)-Br bond strengths
80
 as was observed with analogous 2-aryl-6,8-dibromo-4-
methoxyquinolines.
19 
The absorption and emission properties of compounds 84a-l prepared in this 
investigation showed strong correlation with the substituent on the 2-, 6- and 8-aryl groups. The 
absorption spectra of solutions of these compounds in a polar protic methanol-chloroform mixture 
were characterized by bathochromic and hypsochromic shift as compared to solutions of these 
compounds in non-polar chloroform due to hydrogen bonding with methanol. The solutions of 
2,6,8-triaryl-4-(phenylethynyl)quinazoline exhibited intense emission in non-polar chloroform 
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and polar aprotic dimethylformamide. The prepared 2,6,8-triaryl-4-(phenylethynyl)quinazolines 
84a-l can be used as substrates for possible coordination with metals such as palladium
81
 or 
iridium
82
 because analogous metal complexes have applications in materials and medicinal 
chemistry. Palladium(II) complexes of 8-aminoquinoline analogues, for example, were found to 
interact with extracellular protein responsible for the blood acidity and pressure.
81
 an iridium 
complex containing a phenyl quinazoline ligand, on the other hand, has found application in 
polymer light-emitting diodes.
82
 The molecular architecture of the compounds makes them 
suitable candidates for further studies of chemical transformation and for application in materials 
reseach. Future research extending from this investigation could include the following: 
- Subjecting the 2-aryl-6,8-dibromo-4-(phenylethynyl)quinazolines to Heck, Suzuki or 
Sonogashira cross-coupling  with aryl alkenes, arylvinylboronic acids or aryl alkynes, 
respectively, to afford polyaryl substituted quinazolines, in which the quinazoline core is 
linked to aryl rings via π-conjugated spacers. 
- Synthesis and electrophosphorescence studies of iridium complexes containing 2,6,8-
triaryl-4-(phenylethynyl)quinazolines ligands as a prelude to compounds with potential 
application in light-emitting diodes
82
 
- Synthesis of 2,6,8-triaryl-4-(phenylethynyl)quinazolines palladium(II) complexes with 
potential biological activities in analogy with palladium(II) complexes of 8-
aminoquinoline 
81
 
In conclusion, the results of this investigation represent an application of the 2-aryl-6,8-
dibromo-4-chloroquinazoline in the synthesis of polysubstituted quinazolines. The 
preliminary photophysical properties of compounds 84 serve as a prelude to compounds with 
potential electronic properties. The synthesis of the compounds prepared in this investigation 
60 
 
and the result of photophysical (absorption and emission) property studies of compounds 84 
have since been published.
83
 
 
CHAPTER 4   EXPERIMENTAL 
 
4.1  General 
 
Reagents and solvents were used as supplied or purified by conventional methods. All 
melting points reported were determined on a Stuart melting point apparatus. Merk silica gel 
60 F254 plates were used for thin-layer chromatography and the powder 90% (0.0063-0.10 
mm) and flow time < 80 s / 10 cm was used as stationary phase for column chromatography.  
IR spectra were recorded as powders on a Bruker Vertex 70 FTIR. 
1
H NMR and 
13
C NMR 
spectra were obtained using a Varian Mercury 300 MHz spectrometer. High and low 
resolution mass spectra were recorded on a Waters API Q-TOF Ultima mass spectrometer at 
the University of Stellenbosch. Absorption spectra were recorded on a CECIL CE9500 
spectrophotometer and fluorescence spectra on a Perkin Elmer LS55 spectrometer. The 
quantum efficiencies of fluorescence (Φx) were obtained with the following equation:  
Φx= Φst*(Fx/Fst)*(Ast/Ax)*(nx
2
/nst
2
) 
F denotes the area under the fluorescence band (F = 
a
Ifl(λ), where Ifl(λ) is the fluorescence 
intensity at each emission wavelength), A denotes the absorbance at the excitation 
wavelength, and n is the refractive index of the solvent.
84
 
The following abbreviations are used throughout for NMR spectral data: 
ppm = parts per million; J = coupling constant in Hz; δ = chemical shift values in ppm. 
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Splitting patterns: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m 
= multiplet 
 
4.2 Preparation of 2-amino-3,5-dibromobenzamide 79 
Br
Br
NH2
NH2
O
1
2
3
4
5
6
 
          79 
A mixture of 2-aminobenzamide 8 (5.00 g, 36.7 mmol) and N-bromosuccinimide (14.23 g; 
80.0 mmol) in CHCl3 was stirred at room temperature for 3 hours. After completion of the 
reaction which was monitored by thin-layer chromatography (TLC) using dichloromethane as 
mobile phase, the resulting precipitate was filtered and washed with cold ethanol to afford 79 
as an orange solid (7.51 g, 70%), mp. 215−218 °C; IR (neat): νmax 541, 644, 860, 1240, 1602, 
1641, 3181, 3325, 3369 cm
-1
; 
1
H NMR (300 MHz, DMSO-d6) δ: 6.77 (2H, s, NH2), 7.47 (1H, 
s, NHa), 7.72 (1H, s, ArH), 7.77 (1H, s, ArH), 8,05 (1H, s, NHb); 
13
C NMR (75 MHz, 
DMSO-d6) δ: 105.4 (C-5), 110.8 (C-3), 117.3 (C-4), 131.2 (C-2), 137.2 (C-1), 146.5 (C-6), 
169.7 (C(1)-C) ; m/z (100, MH
+
) 293; HRMS (ES): MH
+
, found 292.8928. C7H7N2O
79
Br2
+
 
requires 292.8925. 
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4.3  Preparation of 2-aryl-6,8-dibromoquinazolin-4(3H)-one derivatives 81a-d        
N
NH
Br
Br
O
R
1
2
3
44a
5
6
7
8
8a
1'
2'
3'
4'
5'
6'
 
81a-d 
 
4.3.1 Preparation of 6,8-dibromo-2-phenylquinazolin-4(3H)-one 81a (4΄-R=H) 
 
A stirred mixture of 79 (1.00 g, 3.3 mmol), iodine (1.90 g, 6.7 mmol) and benzaldehyde 80a 
(0.43 g, 4.0 mmol) in absolute ethanol (100 ml) was heated under reflux for 7 hours. After 
completion of the reaction which was monitored by TLC using dichloromethane as mobile 
phase, water (100 ml) was added to the reaction mixture and the resulting precipitate was 
filtered and washed with aqueous sodium thiosulfate. The solid obtained was recrystallized 
from acetonitrile to afford 81a as a white solid (1.06 g, 80%), mp. 332−335 °C; IR (neat): 
νmax 690, 737, 1562, 1600, 1666, 3092, 3167 cm
-1
; 
1
H NMR (300 MHz, DMSO-d6) δ: 
7.58−7.61 (3H, m, ArH), 8.23−8.26 (3H, m, ArH), 8.39 (1H, s, Ar), 12.54 (1H, s, NH); m/z 
(100, MH
+
) 379; HRMS (ES): MH
+
, found 378.9087. C14H9N2O
79
Br2
+
 requires 378.9082. 
 
4.3.2 Preparation of 6,8-dibromo-2-(4-fluorophenyl)quinazolin-4(3H)-one 81b (4΄-R=F) 
 
An experimental procedure employed for the preparation of 81a was followed using a 
mixture of 2-amino-3,5-dibromobenzamide 79 (1.00 g, 3.3 mmol), iodine (1.90 g, 6.7 mmol), 
4-fluorobenzaldehyde 80b (0.50 g, 4 mmol) in absolute ethanol (100 ml). Work-up and 
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recrystalization afforded 81b as a white solid (1.20 g, 89%), mp. > 345 °C; IR (neat): νmax 
722, 794, 836, 1236, 1583, 1676, 3162 cm
-1
; 
1
H NMR (300 MHz, DMSO-d6) δ: 7.42 (2H, t, J 
9.3 Hz, ArH), 8.19 (1H, s, ArH),  8.28−8.34 (3H, m, ArH), 12.94 (1H, s, NH); m/z (100, 
MH
+
) 397; HRMS (ES): MH
+
, found 396.8975. C14H8N2OF
79
Br2
+ 
requires 396.8987. 
 
4.3.3 Preparation of 6,8-dibromo-2-(4-chlorophenyl)quinazolin-4(3H)-one 81c (4΄-R=Cl) 
 
An experimental procedure employed for the preparation of 81a was followed using a 
mixture of 2-amino-3,5-dibromobenzamide 79 (1.00 g, 3.3 mmol), iodine (1.90 g, 6.7 mmol), 
4-chlorobenzaldehyde 80c (0.56 g, 4.00 mmol) in absolute ethanol (100 ml). Work-up and 
recrystalisation afforded 81c as a white solid (1.37 g, 94%), mp. > 345 °C; IR (neat): νmax  
695, 728, 793, 1558, 1601, 1672, 3154 cm
-1
; 
1
H NMR (300 MHz, DMSO-d6) δ: 7.65 (2H, d, 
J 9.3 Hz, ArH), 8,19 (1H, s, ArH), 8.27 (2H, d, J  9.3 Hz, ArH), 8.34 (1H, s, ArH), 12.98 
(1H, s, NH); m/z (100, MH
+
) 413; HRMS (ES): MH
+
, found 412.8683. C14H8N2O
35
Cl
79
Br2
+ 
requires 414.8692. 
 
4.3.4 Preparation of 6,8-dibromo-2-(4-methoxyphenyl)quinazolin-4(3H)-one  
            81d (4΄-R=OCH3) 
  
An experimental procedure employed for the preparation of 81a was followed using a 
mixture of 2-amino-3,5-dibromobenzamide 79 (1.00 g, 3.3 mmol), iodine (1.90 g, 6.7 mmol), 
4-methoxybenzaldehyde 80d (0.54 g, 4.0 mmol) in absolute ethanol (100 ml). Work-up and 
recrystalisation afforded 81d as a white solid (1.28 g, 89%), mp. 302−304 °C; IR (neat): νmax 
792, 851, 873, 1253, 1556, 1602, 1663, 3167 cm
-1
; 
1
H NMR (300 MHz, DMSO-d6) δ: 3.85 
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(3H, s, CH3), 7.11 (2H, d, J 9.3 Hz, ArH), 8.17 (1H, s, ArH), 8.25−8.31 (3H, m, ArH), 12.73 
(1H, s, ArH); m/z (100, MH
+
) 409; HRMS (ES): MH
+
, found 408.9190. C15H11N2O2
79
Br2
+ 
requires 408.9187. 
 
4.4  Preparation of 2-aryl-4-chloro-6,8-dibromoquinazoline derivatives 82a-d 
N
N
Br
Br
Cl
R
1
2
3
4
4a
5
6
7
8
8a
1'
2'
3'
4'
5'
6'
 
82a-d 
 
4.4.1 Preparation of 6,8-dibromo-4-chloro-2-phenylquinazoline 82a (4΄-R=H) 
 
DMF (1 ml) was added dropwise at room temperature to a stirred mixture of 81a (1.00 g, 2.6 
mmol) and thionyl chloride (30 ml). The reaction mixture was stirred under reflux for 2 hours 
and then allowed to cool to room temperature. Ice-cold water was added to the reaction and 
the mixture was extracted with chloroform. The organic layer was washed with water, dried 
over MgSO4, filtered and evaporated under reduced pressure to afford 82a as a white solid 
(0.99 g, 96%), mp. 185−188 °C; IR(neat) νmax 685, 705, 1297, 1331, 1551, 1582 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ: 7.51−7.56 (3H, m, ArH), 8.30 (1H, d, J 2.1 Hz, ArH), 8.36 (1H, 
d, J 2.1 Hz, ArH), 8.61−8.65 (2H, m, ArH); 13C NMR (75 MHz, CDCl3) δ: 121.2 (C-4a), 
123.9 (C-6), 125.6 (C-5), 127.6 (C-8), 128.7 (C-2′ and C-6′), 129.0 (C-3′ and C-5′), 131.8 (C-
4′), 135.7 (C-1′), 140.9 (C-7), 148.1 (C-8a), 160.6 (C-4), 161.6 (C-2); m/z (100, MH+) 397; 
HRMS (ES): MH
+
, found 396.8733. C14H8N2
35
Cl
79
Br2
+
 requires 396.8743. 
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4.4.2 Preparation of 6,8-dibromo-4-chloro-2-(4-fluorophenyl)quinazoline 82b (4΄-R=F) 
 
A procedure for the preparation of 82a was followed using a mixture of 81b (1.00 g, 2.4 
mmol), thionyl chloride (30 ml) and DMF (1 ml). Work-up afforded 82b as a white solid 
(0.84 g, 81%), mp. 206−208 °C; IR (neat) νmax 721, 769, 848, 1215, 1300, 1332, 1585, 1597 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 7.19 (2H, t, J 8.7 Hz, ArH), 8.30 (1H, d, J 2.1 Hz, ArH), 
8.35 (1H, d, J 2.1 Hz, ArH), 8.63 (2H, t, J 8.7 Hz, ArH); 
13
C NMR (75 MHz, CDCl3) δ: 115.8 
(d, 
2
JCF 21.7 Hz, C-3′ and C-5′), 121.3 (C-4a), 123.8 (C-6), 125.5 (C-5), 127.6 (C-8), 131.3 
(d, 
3
JCF 8.3 Hz, C-2′ and C-6′), 132.0 (d, 
4
JCF 3.2 Hz, C-1′), 141.0 (C-7), 148.1 (C-8a), 159.6 
(C-4), 161.6 (C-2), 165.3 (d, 
1
JCF 251.2 Hz, C-4′); m/z (100, MH
+
) 415; HRMS (ES): MH
+
, 
found 414.8641. C14H7N2F
35
Cl
79
Br2
+
 requires 414.8649. 
 
4.4.3 Preparation of 6,8-dibromo-4-chloro-2-(4-chlorophenyl)quinazoline 82c (4΄-R=Cl) 
 
A procedure for the preparation of 82a was followed using a mixture of 81c (1.00 g, 2.4 
mmol), thionyl chloride (30 ml) and DMF (1 ml). Work-up afforded 82c as a white solid 
(0.80 g, 77%), mp. 239−240 °C; IR(neat) νmax 734, 786, 867, 1298, 1333, 1553, 1578 cm
-1
; 
(300 MHz, CDCl3) δ: 7.50 (2H, t, J 7.8 Hz, ArH), 8.31 (1H, d, J 2.1 Hz, ArH), 8.36 (1H, d, J 
2.1 Hz, ArH), 8.57 (2H, d, J 7.8 Hz, ArH); 
13
C NMR (75 MHz, CDCl3) δ: 121.6 (C-4a), 
124.1 (C-6), 125.6 (C-5), 127.7 (C-8), 129.1 (C-2′ and C-6′), 130.3 (C-3′ and C-5′), 134.4 (C-
1′), 138.2 (C-4′), 141.1 (C-7), 148.1 (C-8a), 159.7 (C-4), 161.8 (C-2); m/z (100, MH+) 431; 
HRMS (ES): MH
+
, found 430.8339. C14H7N2
35
Cl2
79
Br2
+
 requires 430.8353. 
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4.4.4 Preparation of 6,8-dibromo-4-chloro-2-(4-methoxyphenyl)quinazoline 82d (4΄-
R=OCH3) 
 
A procedure for the preparation of 82a was followed using a mixture of 81d (1.00 g, 2.4 
mmol), thionyl chloride (30 ml) and DMF (1 ml). Work-up afforded 82d as a yellow solid 
(1.02 g, 91%), mp. 200−202 °C; IR(neat) νmax  728, 766, 1026, 1297, 1335, 1554,1583, 1607 
cm
-1
; (300 MHz, CDCl3) δ: 3.89 (3H, s, CH3), 7.00 (2H, d, J 8.7 Hz, ArH), 8.25 (1H, d, J 2.1 
Hz, ArH), 8.30 (1H, d, J 2.1 Hz, ArH), 8.56 (2H, d, J 8.7 Hz, ArH); 
13
C NMR (75 MHz, 
CDCl3) δ: 55.4 (OCH3), 114.1 (C-3′ and C-5′), 120.5 (C-4a), 123.6 (C-6), 125.3 (C-5), 127.6 
(C-8), 128.5 (C-2′ and C-6′), 130.9 (C-1′), 140.8 (C-7), 148.2 (C-8a), 160.5 (C-4), 161.4 (C-
4΄), 162.8 (C-2); m/z (100, MH+) 427; HRMS (ES): MH+, found 426.8841. 
C15H10N2O
35
Cl
79
Br2
+
 requires 426.8848. 
 
4.5  Preparation of 2-aryl-6,8-dibromo-4-(alkynyl)quinazoline derivatives 83a-h  
N
N
Br
Br
R
1
2
3
4
4a
5
6
7
8
8a
1'
2'
3'
4'
5'
6'
1''
2''
3''
4''
5''
6''
       
N
N
Br
Br
R
N
5
6
7
8
8a
4a
1
2
3
4
1'
2'
3'
4'
5'
6'
1''
2''
3''
4''
5''
6''
   
N
N
Br
Br
R
CH3HO
5
6
7
8
8a
4a
1
2
3
4
1'
2'
3'
4'
5'
6'
 
83a-d (R=H, F, Cl, OCH3)        83e-g (R=H, F, OCH3)         83h (R=H) 
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4.5.1 Preparation of 6,8-dibromo-2-phenyl-4-(phenylethynyl)quinazoline 83a (4΄-R=H) 
 
A mixture of 82a (0.50 g, 1.3 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 
mmol) and Cs2CO3 (0.60 g, 1.7 mmol) in THF (30 ml) was purged with argon gas. Phenyl 
acetylene (0.14 g, 1.4 mmol) was added using a syringe. The reaction mixture was stirred at 
room temperature for 24 hours. Water was then added and the mixture was extracted with 
chloroform. The organic layer was washed with water, dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude residue was purified using column 
chromatography on silica gel to afford 83a as a yellow solid (0.35 g, 59%), Rf (petroleum 
ether, toluene 1/1) 0.58, mp. 192−195 °C; IR (neat): νmax 678, 730, 752, 777, 1525, 1670, 
2215 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 744−7.49 (6H, m, ArH), 7.77 (2H, d, J 7.5 Hz, 
ArH), 8.28 (1H, s, ArH), 8.47 (1H, s, ArH), 8.70 (2H, t, J 3.3 Hz, ArH);
 13
C NMR (75 MHz, 
CDCl3) δ: 84.9 (Ph-C≡), 99.1 (C(4)-C≡), 120.7 (C-6), 120.8 (C-1″), 125.4 (C-4a), 125.9 (C-
8), 128.3 (C-2′ and C-6′), 128.6 (C-3″ and C-5″), 128.7 (C-4″), 129.0 (C-4′), 130.5 (C-5), 
131.3 (C-1′), 132.7 (C-3′ and C-5′), 136.9 (C-2″ and C-6″), 140.2 (C-7), 147.2 (C-8a), 152.3 
(C-4), 161.5 (C-2); m/z (100, MH
+
) 463; HRMS (ES): MH
+
, found 462.9435. C22H13N2
79
Br2
+ 
requires 462.9445. 
 
4.5.2 Preparation of 6,8-dibromo-2-(4-fluorophenyl)-4-(phenylethynyl)quinazoline 83b     
            (4΄-R=F) 
 
An experimental procedure employed for the preparation of 83a was followed using a mixture 
of 82b (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), Cs2CO3 
(0,60 g, 1.7 mmol) and phenyl acetylene (0.14 g, 1.4 mmol) in THF (30 ml). Work-up and 
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column chromatography afforded 83b as a yellow solid (035 g, 59%), Rf (petroleum ether, 
toluene 1/1) 062, mp. 217−220 °C; IR (neat): νmax  683, 753, 802, 872, 1527, 1601, 2210 cm
-1
. 
1
H NMR (300 MHz, CDCl3) δ: 7.20 (2H, t, J 7.8 Hz, ArH), 7.45−749 (3H, m, ArH), 7.77 (2H, 
d, J 6 Hz, ArH), 8.29 (1H, s, ArH),  8.46 (1H, s, ArH), 8.71 (2H, dd, J 9.3, 6 Hz, ArH);
 13
C 
NMR (75 MHz, CDCl3) δ: 84.8 (Ph-C≡), 99.3 (C(4)-C≡), 115.6 (d, 
2
JCF 21.6 Hz, C-3΄ and C-
5′), 120.6 (C-6), 120.7 (C-1″), 125.3 (C-4a), 125.7 (C-8), 128.3 (C-3″ and C-5″), 128.5 (C-4″), 
130.6 (C-2″ and C-6″), 131.2 (d, 3JCF 8.8 Hz, C-2′ and C-6′), 132.7 (C-5), 133.1 (d, 
4
JCF 3.4 
Hz, C-1′), 140.4 (C-7), 147.2 (C-8a), 152.4 (C-4), 160.6 (C-2), 165.1 (d, 1J CF 250.2 Hz, C-4′); 
m/z (100, MH
+
) 481; HRMS (ES): MH
+
, found 480.9347. C22H12N2F
79
Br2
+ 
requires 480.9351. 
 
4.5.3 Preparation of 6,8-dibromo-2-(4-chlorophenyl)-4-(phenylethynyl)quinazoline 83c  
            (4΄-R=Cl) 
 
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82c (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and phenyl acetylene (0.14 g, 1.4 mmol) in THF (30 ml). Work-
up and column chromatography afforded 83c as a yellow solid (0.40 g, 70%), Rf (petroleum 
ether, toluene 1/1) 0.7, mp. 223−226 °C; IR (neat): νmax 683, 748, 801, 868, 1467, 1524, 
1544, 2209 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.45−750 (5H, m, ArH), 7.77 (2H, d, J 6 Hz, 
ArH), 8.29 (1H, s, ArH), 8.46 (1H, s, ArH), 8.64 (2H, d, J 9.3 Hz, ArH);
 13
C NMR (75 MHz, 
CDCl3) δ: 84.8 (Ph-C≡), 99.4 (C(4)-C≡), 120.7 (C-6), 121.0 (C-1″), 125.5 (C-4a), 125.8 (C-
8), 128.3 (C-3″ and C-5″), 128.8 (C-4″), 128.9 (C-1′), 130.3 (C-2′ and C-6′), 130.6 (C-5), 
132.7 (C-3′ and C-5′), 135.4 (C-2″ and C-6″), 137.7 (C-4′), 140.4 (C-7), 147.2 (C-8a), 152.4 
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(C-4), 160.6 (C-2); m/z (100, MH
+
) 497; HRMS (ES): MH
+
, found 496.8040. 
C22H12N2
35
Cl
79
Br2
+ 
requires 496.8056. 
 
4.5.4 Preparation of 6,8-dibromo-2-(4-methoxyphenyl)-4-(phenylethynyl)    
            quinazoline 83d (4΄-R=OCH3) 
 
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82d (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and phenyl acetylene (0.14 g, 1.4 mmol) in THF (30 ml). Work-
up and column chromatography afforded 83d as a yellow solid (0.42 g, 71%), Rf (petroleum 
ether, toluene 1/1) 0.3, mp. 194−198 °C; IR (neat): νmax 722, 801, 828, 1255, 1524, 1543, 
2210 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.89 (3H, s, CH3), 7.03 (2H, d, J 7.2 Hz, ArH), 
7.40−7.48 (3H, m, ArH), 7.76 (2H, d, J 6.9 Hz, ArH), 8.26 (1H, s, ArH), 8.44 (1H, s, ArH), 
8.64 (2H, d, J 6.9 Hz, ArH);
 13
C NMR (75 MHz, CDCl3) δ: 55.4 (OCH3), 85.0 (Ph-C≡),  98.7 
(C(4)-C≡), 114.0 (C-3 and C-5), 120.0 (C-6), 120.8 (C-1″), 125.1 (C-1′), 125.6 (C-4a), 128.3 
(C-8), 128.7 (C-3″ and C-5″), 129.9 (C-2′ and C-6′), 130.5 (C-4″), 130.8 (C-5), 132.7 (C-2″ 
and C-6″), 140.1(C-7), 147.4 (C-8a), 152.2 (C-4), 161.4 (C-4′), 162.4 (C-2); m/z (100, MH+) 
493; HRMS (ES): MH
+
, found 492.9541. C23H15N2O
79
Br2
+ 
requires 492.9551. 
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4.5.5 Preparation of 6,8-dibromo-2-phenyl-4-(pyridin-2-ylethynyl)quinazoline 83e (4΄-
R=H) 
  
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82a (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and 2-ethynylpyridine (0.14 g, 1.3 mmol) in THF (30 ml). Work-
up and column chromatography afforded 83e as an orange solid (0.36 g, 65%), Rf (toluene) 
0.15, mp. 207−209 °C; IR (neat): νmax  688, 733, 775, 1304, 1464, 1527, 1543, 2228 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ:  7.39−7.44 (1H, m, ArH), 7.54−7.55 (4H, m, ArH), 7.78−7.82 
(2H, m, ArH), 8.30 (1H, s, ArH), 8.54 (1H, s, ArH), 8.69−8.76 (2H, m, ArH); 13C NMR (75 
MHz, CDCl3) δ: 83.5 (C″(1)-C≡), 96.4 (C(4)-C≡), 121.1 (C-6), 124.5 (C-4″), 125.5 (C-4a), 
125.9 (C-8), 128.2 (C-2′ and C-6′), 128.6 (C-2″), 128.7 (C-4′), 130.0 (C-5), 131.4 (C-3′ and 
C-5′), 136.5 (C-1′), 136.8 (C-3″), 140.6 (C-7), 141.5 (C-1′), 147.4 (C-5″), 150.6 (C-8a), 151.7 
(C-4), 161.5 (C-2); m/z (100, MH
+
) 464; HRMS (ES): MH
+
, found 463.9398. C21H12N3
79
Br2
+ 
requires 463.9398. 
 
4.5.6 Preparation of 6,8-dibromo-2-(4-fluorophenyl)-4-(pyridin-2-
ylethynyl)quinazoline 83f (4΄-R=F) 
 
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82b (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and 2-ethynylpyridine (0.14 g, 1.3 mmol) in THF (30 ml). Work-
up and column chromatography afforded 83f as an orange solid (0.38 g, 67%), Rf (toluene) 
0.2, mp. 216−218 °C; IR (neat): νmax 702, 777, 802, 1306, 1409, 1465, 1527, 2219 cm
-1
; 
1
H 
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NMR (300 MHz, CDCl3) δ: 7.21 (2H, t, J 7.8 Hz, ArH), 7.42−7.44 (1H, m, ArH), 7.81−7.86 
(2H, m, ArH), 8.30 (1H, s, ArH), 8.54 (1H, s, ArH), 8.69−8.78 (3H, m, ArH); 13C NMR (75 
MHz, CDCl3) δ: 83.4 (C″(1)-C≡), 96.6 (C(4)-C≡), 115.6 (d, 
2
JCF 21.6 Hz), 121.1 (C-6), 124.6 
(C-4″), 125.4 (C-4a), 125.7 (C-8), 128.3 (C-2″), 128.6 (C-5), 131.3 (d, 3JCF 8.8 Hz, C-3΄ and 
C-5′), 133.1 (d, 4JCF 3.4 Hz, C-2′ and C-6′), 136.5 (C-3″), 140.7 (C-7), 141.4 (C-1″), 147.4 
(C-5″), 150.7 (C-8a), 151.7 (C-4), 160.6 (C-2), 165.1 (d, 1JCF 250.2 Hz, C-4′); m/z (100, 
MH
+
) 482; HRMS (ES): MH
+
, found 481.9301. C21H11N3F
79
Br2
+ 
requires 481.9304. 
 
4.5.7 Preparation of 6,8-dibromo-2-(4-methoxyphenyl)-4-(pyridin-2-
ylethynyl)quinazoline 83g (4΄-R=OCH3) 
  
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82d (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and 2-ethynylpyridine (0.14 g, 1.3 mmol) in THF (30 ml). Work-
up and column chromatography afforded 83g as an orange solid (0.32 g, 55%), Rf (toluene) 
0.2, mp. 204−206 °C; IR (neat): νmax 723, 801, 868, 1023, 1163, 1258, 1525, 2221 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ:  3.90 (3H, s, CH3), 7.03 (2H, d, J 8.7 Hz, ArH), 7.40−743 (1H, 
m, ArH), 7.79−7.77 (2H, m, ArH), 8.26 (1H, s, ArH), 8.50 (1H, s, ArH), 8.65 (2H, d, J 8.7 
Hz, ArH), 8.74 (1H, s, ArH);
 13
C NMR (75 MHz, CDCl3) δ: 55.4 (OCH3), 83.6 (C″(1)-C≡), 
96.1 (C(4)-C≡), 114.0 (C-3′ and C-5′), 120.3 (C-6), 124.5 (C-1′), 125.1 (C-4″), 125.6 (C-4a), 
128.2 (C-8), 128.5 (C-2″), 129.5 (C-2′ and C-6′), 130.8 (C-5), 136.4 (C-3″), 140.4 (C-7), 
141.5 (C-1″), 147.4 (C-5″), 150.7 (C-8a), 151.4 (C-4), 161.3 (C-4′), 162.4 (C-2); m/z (100, 
MH
+
) 494; HRMS (ES): MH
+
, found 493.9517. C22H14N3O
79
Br2
+ 
requires 493.9504. 
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4.5.8 Preparation of 4-(6,8-dibromo-2-phenylquinazolin-4-yl)but-3-yn-2-ol 83h  
 
An experimental procedure employed for the preparation of 83a was followed using a 
mixture of 82a (0.50 g, 1.2 mmol), Pd(PPh3)4 (0.07 g, 0.06 mmol), CuI (0.01 g, 0.06 mmol), 
Cs2CO3 (0,60 g, 1.7 mmol) and 3-butyn-2-ol (0.12 g, 1.7 mmol) in THF (30 ml). Work-up 
and column chromatography afforded 83h as a brown solid (0.28 g, 56%), Rf (ethyl acetate, 
hexane 1/1) 0.7, mp. 162−165 °C; IR (neat): νmax 682, 703, 734, 1304, 1365, 1457, 1529, 
2221, 3372 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ:  1.68 (3H, d, J 6.6 Hz, CH3), 2.97 (1H, s, 
OH), 4.90−4.92 (1H, q, J 6.6 Hz, CH), 7.48−7.50 (3H, m, ArH), 8.17 (1H, s, ArH), 8.55−859 
(3H, m, ArH); 
13
C NMR (75 MHz, CDCl3) δ:  23.6 (CH3), 58.6 (CHOH), 79.4 (C(4)-C≡), 
100.9 (C(CH3)-C≡), 120.8 (C-6), 125.0 (C-4a), 125.7 (C-8), 127.9 (C-2′ and C-6′), 128.6 (C-
4′), 128.9 (C-5), 131.4 (C-3′ and C-5′), 136.5 (C-1′), 140.3 (C-7), 147.0 (C-8a), 151.6 (C-4), 
161.2 (C-2); m/z (100, MH
+
) 433; HRMS (ES): MH
+
, found 432.9371. C22H14N3O
79
Br2
+ 
requires 432.9371. 
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4.6  Preparation of 2,6,8-triaryl-4-(phenylethynyl)quinazoline derivatives 84a-l 
N
N
R''
R''
R
 
         84a-l 
 
4.6.1 Preparation of 2,6,8-triphenyl-4-(phenylethynyl)quinazoline 84a (R=H, R”=H)  
 
A mixture of 83a (0.30 g, 0.6 mmol), phenylboronic acid (0.20 g; 1.6 mmol), PdCl2(PPh3)2 
(0.02 g, 0.03 mmol), PCy3 (0.02 g, 0.06 mmol) and K2CO3 (0.23 g, 1.6 mmol) in dioxane-
water (3:1 v/v, 20 ml)  was purged with nitrogen gas. The mixture was then heated with 
stirring at 80 °C under nitrogen atmosphere for 2 hours and allowed to cool to room 
temperature. The reaction mixture was poured into ice-cold water and extracted with 
chloroform. The organic layer was washed with water and brine, then dried over MgSO4 and 
filtered. The filtrate was concentrated under reduced pressure and the residue was purified 
using a column chromatography on silica gel to afford 84a as a yellow solid (0.18 g, 71%), Rf 
(hexane, toluene 1/1) 0.4, mp. 184−186 °C; IR (neat): νmax 687, 718, 755, 1534, 1561, 2208 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 7.43−7.60 (12H, m, ArH), 7.77−7.82 (4H, m, ArH), 
7.90 (2H, d, J 7.5 Hz, ArH), 8.24 (1H, s, ArH), 8.57−8.59 (3H, m, ArH); 13C NMR (75 MHz, 
CDCl3) δ:  85.9, 97.7, 121.3, 123.3, 124.5, 127.4, 127.8, 127.9, 128.1, 128.5, 128.6, 128.7, 
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128.9, 129.1, 130.1, 130.6, 131.0, 132.5, 134.2, 137.8, 137.9, 139.9, 140.1, 140.7, 147.9, 
153.1, 160.0; m/z (100, MH
+
) 459; HRMS (ES): MH
+
, found 459.1870. C34H23N2
+ 
requires 
459.1861. 
 
4.6.2 Preparation of 2-(4-fluorophenyl)-6,8-diphenyl-4-(phenylethynyl)quinazoline 84b 
(R=F, R”=H)  
 
A mixture of 83b (0.20 g, 0.4 mmol), phenylboronic acid (0.13 g, 1.0 mmol), PdCl2(PPh3)2 
(0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.0mmol) in dioxane-
water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up and column 
chromatography on silica gel afforded 84b as a yellow solid (0.12 g, 57%), Rf (hexane, 
toluene 1/1) 0.54, mp. 250−252 °C; IR (neat): νmax 686, 741, 812, 1558, 1574, 2210 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ: 7.14 (2H, t, J 8.7 Hz, ArH), 7.42−7.60 (9H, m, ArH), 7.75−7.81 
(4H, m, ArH), 7.87 (2H, d, J 8.1 Hz, ArH), 8.22 (1H, s, ArH), 8.53−8.58 (3H, m, ArH); 13C 
NMR (75 MHz, CDCl3) δ:  85.8, 97.9, 115.4 (d, 
2
JCF 21.6 Hz), 121.3, 123.3, 124.4, 127.4, 
127.8, 128.0, 128.2, 128.6, 129.1, 130.1, 130.8 (d, 
3
JCF 8.8 Hz), 130.9, 132.5, 133.9 (d, 
4
JCF 3 
Hz), 134.3, 137.8, 139.8, 140.1, 140.6, 147.8, 153.1, 159.0, 164.6 (d, 
1
JCF 255 Hz); m/z(100, 
MH
+
) 477; HRMS (ES): MH
+
, found 477.1772. C34H22FN2
+ 
requires 477.1767. 
 
4.6.3 Preparation of 2-(4-chlorophenyl)-6,8-diphenyl-4-(phenylethynyl)quinazoline 84c 
(R=Cl, R”=H)  
 
A mixture of 83c (0.20 g, 0.4 mmol), phenylboronic acid (0.12 g, 1.0 mmol), PdCl2(PPh3)2 
(0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.0 mmol) in dioxane-
75 
 
water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up and column 
chromatography on silica gel afforded 84c as a yellow solid (0.16 g, 78%), Rf (hexane, 
toluene 1/1) 0.6, mp. 246−248 °C; IR (neat): νmax  686, 739, 752, 1557, 1576, 2211 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ: 7.42−7.59 (11H, m, ArH) 7.78−7.80 (4H, m, ArH), 7.87 (2H, d, 
J 6.9, ArH), 8.23 (1H, s, ArH), 8.51 (2H, d, J 8.7 Hz, ArH), 8.57 (1H, s, ArH);
 13
C NMR (75 
MHz, CDCl3) δ:  85.8, 98.0, 121.2, 123.2, 124.5, 127.4, 127.8, 128.0, 128.2, 128.6, 128.7, 
129.1, 130.1, 130.9, 132.5, 134.3, 136.3, 136.7, 137.8, 139.7, 140.2, 140.7, 147.8, 153.1, 
159.0; m/z (100, MH
+
) 493; HRMS (ES): MH
+
, found 493.1475. C34H22ClN2
+ 
requires 
493.1472. 
 
4.6.4 Preparation of 2-(4-methoxyphenyl)-6,8-diphenyl-4-(phenylethynyl)quinazoline 
84d (R=OCH3, R”=H)  
 
A mixture of 83d (0.20 g, 0.4 mmol), phenylboronic acid (0.13 g, 1.0 mmol), PdCl2(PPh3)2 
(0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.0 mmol) in dioxane-
water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up and column 
chromatography on silica gel afforded 83d as a yellow solid (0.14 g, 68%), Rf (hexane, 
toluene 1/2) 0.17, mp. 220−223 °C; IR (neat): νmax 685, 699, 752, 1161, 1247, 1533, 2205 cm
-
1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.88 (3H, s, ArH), 7.01 (2H, d, J 7.5 Hz, ArH), 7.43−7.59 
(9H, m, ArH), 7.78−7.81 (4H, m, ArH), 7.89 (2H, d, J 7.5 Hz, ArH), 8.22 (1H, s, ArH), 
8.51−8.54 (3H, m, ArH); 13C NMR (75 MHz, CDCl3) δ:  55.3, 86.0, 97.5, 113.8, 121.4, 
123.3, 124.2, 127.4, 127.7, 127.9, 128.0, 128.4, 128.6, 129.1, 130.0, 130.3, 130.5, 130.9, 
132.5, 134.1, 138.0, 139.5, 140.0, 140.4, 148.0, 153.0, 159.8, 161.8; m/z (100, MH
+
) 489; 
HRMS (ES): MH
+
, found 489.1976. C35H25ON2
+ 
requires 489.1967. 
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4.6.5 Preparation of 6,8-bis(4-fluorophenyl)-2-phenyl-4-(phenylethynyl)quinazoline 84e 
(R=H, R”=F)  
 
A mixture of 83a (0.20 g, 0.43 mmol), 4-fluorophenylboronic acid (0.15 g, 1.07 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3(0.01 g, 0.04 mmol) and K2CO3 (0.15 g, 1.1 mmol) in 
dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 83e as a yellow solid (0.14 g, 66%), Rf 
(hexane, toluene 1/1) 0.48, mp. 228−230 °C; IR (neat): νmax 691, 708, 825, 1232, 1509, 2205 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 7.44−7.49 (6H, m, ArH), 7.72−7.79 (4H, m, ArH), 7.85 
(2H, ddd, J 3.3, 6.45, 9.15 Hz, ArH), 8.12 (1H, d, J 2.1 Hz, ArH), 8.49 (1H, d, 2.1 Hz, ArH), 
8.55 (2H, dd, J 2.1, 7.0 Hz, ArH); 
13
C NMR (75 MHz, CDCl3) δ:  85.8, 97.9, 114.9 (d 
2
JCF 
21.3 Hz), 116.1 (d, 
2
JCF 21.3 Hz) 121.3, 123.2, 124.5, 128.5 (d,
3
JCF 8.3 Hz), 128.7, 129.1 
(d,
3
JCF 8.2 Hz), 130.1, 130.7, 132.5, 132.6, 133.7 (d, 
4
JCF 3.4 Hz), 133.8, 135.9 (d, 
4
JCF 3.1 
Hz), 137.6, 139.8, 147.7, 153.1, 160.1, 162.7 (d, 
1
JCF 245.9 Hz), 162.9 (d,
 1
JCF 246.9 Hz); m/z 
(100, MH
+
) 495; HRMS (ES): MH
+
, found 495.1685. C34H21F2N2
+ 
requires 495.1673. 
 
4.6.6 Preparation of 2,6,8-tris(4-fluorophenyl)-4-(phenylethynyl)quinazoline 84f (R=F, 
R”=F)  
 
A mixture of 83b (0.20 g, 0.4 mmol), 4-fluorophenylboronic acid (0.15 g, 1.1 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.15 g, 1.1 mmol) 
in dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84f as a yellow solid (0.16 g, 76%), Rf 
(hexane, toluene 1/1) 0.58, mp. 255−257 °C; IR (neat): νmax 685, 750, 824, 1232, 1536, 2207 
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cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 7.12−7.29 (6H, m, ArH), 7.47−7.49 (3H, m, ArH), 
7.72−7.85 (6H, m, ArH), 8.12 (1H, d, J 2.1 Hz, ArH), 8.49 (1H, d, 2.1 Hz, ArH), 8.54 (2H, 
dd, J 3, 8.8 Hz, ArH); 
13
C NMR (75 MHz, CDCl3) δ:  85.7, 98.1, 114.9 (d, 
2
JCF 21.3 Hz), 
115.5 (d, 
2
JCF 21.6 Hz), 116.1 (d, 
2
JCF 21.6 Hz)  121.2, 123.2, 124.3, 128.5, 128.7, 129.1(d, 
3
JCF  8.2 Hz), 130.2, 130.7 (d, 
3
JCF 8.7 Hz), 132.4 (d, 
3
JCF 8.1 Hz), 132.5, 132.6, 133.6 (d, 
4
JCF 
3.1 Hz), 133.8 (d, 
4
JCF 2.8 Hz), 133.9, 135.8 (d, 
4
JCF 3.1 Hz), 139.0, 139.7, 147.7, 153.1, 
159.2 , 162.7 (d, 
1
JCF 245.9 Hz), 162.9 (d,
 1
JCF 246.9 Hz), 164.6 (d, 
1
JCF 247.5 Hz); m/z (100, 
MH
+
) 513; HRMS (ES): MH
+
, found 513.1585. C34H20F3N2
+ 
requires 513.1579. 
 
4.6.7 Preparation of 6,8-bis(4-fluorophenyl)-2-(4-chlorophenyl)-4-(phenylethynyl) 
quinazoline 84g (R=Cl, R”=F)  
 
A mixture of 83c (0.20 g, 0.4 mmol), 4-fluorophenylboronic acid (0.14 g, 1.1 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.1 mmol) 
in dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84g as a yellow solid (0.16 g, 75%), Rf 
(hexane, toluene 1/1) 0.72, mp. 243−245 °C; IR (neat): νmax 683, 747, 809, 1231, 1508, 2205 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 7.24 (4H, dd, J 6.9, 15.3, ArH) 7.44−7.49 (6H, m, 
ArH), 7.43−7.51 (5H, m, ArH), 7.72−7.84 (6H, m, ArH), 8.12 (1H, d, J 2.4 Hz, ArH), 
8.46−8.49 (3H, m, ArH); 13C NMR (75 MHz, CDCl3) δ:  85.7, 98.2, 114.9 (d 
2
JCF 21.3 Hz), 
116.1 (d, 
2
JCF 21.3 Hz) 121.1, 123.1, 124.4, 128.7, 128.8, 129.1 (d, 
3
JCF 8.2 Hz), 129.9, 130.2, 
132.4 (d, 
3
JCF 8.3 Hz), 132.5, 133.6 (d,
4
JCF 3.3 Hz), 133.8, 135.8 (d,
4
JCF 3.3 Hz), 136.1, 
136.9, 139.1, 139.7, 147.6, 153.1, 159.0, 162.7 (d, 
1
JCF 246.2 Hz), 163.0 (d,
 1
JCF 247.0 Hz); 
m/z (100, MH
+
) 529; HRMS (ES): MH
+
, found 529.1282. C34H20ClF2N2
+
requires 529.1283. 
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4.6.8 Preparation of 6,8-bis(4-fluorophenyl)-2-(4-methoxyphenyl)-4-(phenylethynyl) 
quinazoline 84h (R=OCH3, R”=F)  
 
A mixture of 83d (0.20 g, 0.4 mmol), 4-fluorophenylboronic acid (0.14 g, 1.1 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3(0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.1 mmol) in 
dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84h as a yellow solid (0.14 g, 65%), Rf 
(hexane, toluene 1/2) 0.5, mp. 211−213 °C; IR (neat): νmax 683, 750, 809, 1157, 1507, 2205 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.87 (3H, s, ArH), 6.99 (3H, d, J 7.8, ArH), 7.24−7.21 
(4H, m, ArH), 7.47 (3H, s, ArH), 7.83−7.73 (5H, m, ArH), 8.06 (1H, s, ArH), 8.48 (3H, t, J 
7.8 Hz, ArH); 
13
C NMR(75 MHz, CDCl3) δ:  55.3, 85.9, 97.6, 113.8, 114.9 (d 
2
JCF 21.3 Hz), 
116.1 (d, 
2
JCF 21.3 Hz) 121.3, 123.1, 124.1, 128.5, 128.7, 129.0 (d, 
3
JCF 8.2 Hz), 130.1, 130.3, 
131.7, 132.5, 132.6 (d, 
3
JCF 8.5 Hz),, 133.7, 133.8 (d, 
4
JCF 3.1 Hz), 135.9 (d, 
4
JCF 3.1 Hz), 
138.4, 139.4, 147.8, 152.9, 159.9, 161.8 162.7 (d, 
1
JCF 245.5 Hz), 162.9 (d,
 1
JCF 246.7 Hz); 
m/z (100, MH
+
) 525; HRMS (ES): MH
+
, found 525.1785. C35H23OF2N2
+ 
requires 525.1778. 
 
4.6.9 Preparation of 6,8-bis(4-methoxyphenyl)-2-phenyl-4-(phenylethynyl)quinazoline      
84i (R=H, R”=OCH3)  
 
A mixture of 83a (0.30 g, 0.6 mmol), 4-methoxyphenylboronic acid (0.20 g, 1.6 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.23 g, 1.6 mmol) 
in dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84i as a yellow solid (0.23 g, 69%), Rf 
(hexane, toluene 1/2) 0.28, mp. 209−212 °C; IR (neat): νmax 691, 758, 831, 1243, 1510, 2209 
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cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.89 (3H, s, CH3), 3.93 (3H, s, CH3), 7.07 (4H, dd, J 
8.4, 12.6 Hz, ArH), 7.17 (2H, d, J 2.1 Hz, ArH), 7.44−7.47 (6H, m, ArH), 7.72−7.80 (4H, m, 
ArH), 7.86 (2H, d, J 8.7 Hz, ArH), 8.47 (1H, d, J 2.1 Hz, ArH), 8.56−8.60 (2H, m, ArH); 13C 
NMR (75 MHz, CDCl3) δ:  55.3, 86.0, 97.5, 113.4, 114.5, 121.4, 121.7, 124.5,128.4, 128.5, 
129.9, 130.3, 130.4, 132.1, 132.4, 133.4, 137.8, 139.5, 133.9, 140.0, 147.5, 152.7, 159.3, 
159.4, 159.7; m/z (100, MH
+
) 519; HRMS (ES): MH
+
, found 519.2071. C36H27O2N2
+ 
requires 
519.2073. 
 
4.6.10 Preparation of 2-(4-fluorophenyl)-6,8-bis(4-methoxyphenyl)-4-(phenylethynyl) 
quinazoline 84j (R=F, R”=OCH3)  
 
A mixture of 83b (0.40 g, 0.8 mmol), 4-methoxyphenylboronic acid (0.26 g, 2.1 mmol), 
PdCl2(PPh3)2 (0.03 g, 0.04 mmol), PCy3(0.02 g, 0.08 mmol) and K2CO3 (0.30 g, 2.1 mmol) 
and dioxane-water (3:1 v/v, 30 ml) was treated as described for the synthesis of 84a. Work-
up and column chromatography on silica gel afforded 84j as a yellow solid (0.29 g, 62%), Rf 
(hexane, toluene 1/2) 0.33, mp. 236−239 °C; IR (neat): ν
max
 760, 808, 831, 1248, 1508, 2208 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.89 (3H, s, CH3), 3.93 (3H, s, CH3),  7.04−7.17 (6H, 
m, ArH), 7.44−7.47 (3H, m, ArH), 7.70−7.83 (6H, m, ArH), 8.16 (1H, s, ArH), 8.45 (1H, s, 
ArH), 8.56 (2H, t, J 5.4 Hz, ArH); 
13
C NMR (75 MHz, CDCl3) δ: 55.3, 55.4, 85.9, 97.7, 
113.4, 114.5, 115.4 (d, 
2
JCF 21.3 Hz), 121.3, 121.9, 124.5, 128.5, 128.6, 130.0, 130.3,130.6 
(d,
3
JCF 8.4 Hz), 132.0, 132.2, 132.5,133.6, 134 (d, 
4
JCF 3.0 Hz), 139.7, 140.1, 147.6, 152.8, 
158.6, 159.8, 164.5 (d, 
1
JCF 247.5 Hz); m/z(100, MH
+
) 537; HRMS (ES): MH
+
, found 
537.1986. C36H26O2FN2
+ 
requires 537.1978. 
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4.6.11 Preparation of 2-(4-chlorophenyl)-6,8-bis(4-methoxyphenyl)-4-(phenylethynyl) 
quinazoline 84k (R=Cl, R”=OCH3)  
 
A mixture of 83c (0.30 g, 0.6 mmol), 4-methoxyphenylboronic acid (0.20 g, 1.6 mmol), 
PdCl2(PPh3)2 (0.02 g, 0.03 mmol), PCy3 (0.02 g, 0.06 mmol) and K2CO3 (0.23 g, 1.6 mmol) 
in dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84k as a yellow solid (0.27 g, 76%), Rf 
(hexane, toluene 1/2) 0.38, mp. 233−235 °C; IR (neat): νmax 746, 807, 830, 1248, 1511, 2210 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.88 (3H, s, CH3), 3.92 (3H, s, CH3), 7.42−7.59 (11H, 
m, ArH), 7.78−7.80 (4H, m, ArH), 7.87 (2H, d, J 6.9, ArH), 8.23 (1H, s, ArH), 8.51 (2H, d, J 
8.7 Hz, ArH), 8.57 (1H, s, ArH); 
13
C NMR (75 MHz, CDCl3) δ: 55.3, 55.4, 85.9, 97.8, 113.4, 
114.6, 115.4, 121.3, 121.8, 124.6, 128.5, 128.6, 128.7, 129.9 130.1, 130.2, 130.6, 132.0, 
132.2, 132.5, 133.6, 136.4, 136.6, 138.2, 140.1, 147.6, 152.8, 158.6, 159.4, 159.8; m/z (100, 
MH
+
) 553; HRMS (ES): MH
+
, found 553.1689. C36H26O2ClN2
+ 
requires 553.1683. 
 
4.6.12 Preparation of 2,6,8-tris(4-methoxyphenyl)-4-(phenylethynyl)quinazoline 84l 
(R=OCH3, R”=OCH3)  
 
A mixture of 83d (0.20 g, 0.4 mmol), 4-methoxyphenylboronic acid (0.15 g, 1.0 mmol), 
PdCl2(PPh3)2 (0.01 g, 0.02 mmol), PCy3 (0.01 g, 0.04 mmol) and K2CO3 (0.14 g, 1.0 mmol) 
in dioxane-water (3:1 v/v, 20 ml) was treated as described for the synthesis of 84a. Work-up 
and column chromatography on silica gel afforded 84l as a yellow solid (0.13 g; 60%), Rf 
(hexane, toluene 1/2) 0.2, mp 237−239 °C; IR (neat): νmax 685, 753, 808, 8.32, 1243, 1491, 
2207 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 3.87 (3H, s, CH3), 3.88 (3H, s, CH3), 3.93 (3H, s, 
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CH3), 6.98−7.12 (6H, m, ArH) 7.47 (3H, s, ArH), 7.78−7.80 (4H, m, ArH), 7.81−7.86 (6H, 
m, ArH), 8.16 (1H, s, ArH), 8.46 (1H, s, ArH), 8.55 (2H, d, J 9.3 Hz, ArH);
 13
C NMR (75 
MHz, CDCl3) δ: 55.3, 55.3, 55.4, 86.1, 97.2, 113.3, 113.7, 114.5, 121.4, 121.8, 124.3, 128.4, 
128.5, 129.9, 130.2 130.4, 130.6, 132.1, 132.3, 132.4, 133.4, 139.0,  139.8, 147.6, 152.6, 
159.3, 159.4, 159.7, 161.6; m/z (100, MH
+
) 549; HRMS (ES): MH
+
, found 549.2192. 
C37H29O3N2
+ 
requires 549.2178. 
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